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“You’ve got the future on your side 
You’re gonna be fine now 
I know whatever you decide 
You’re gonna shine” 
 




Human skin is highly compartmentalised and distinct subsets of dendritic cells (DCs) and T 
cells reside in epidermis and dermis. Alterations in the composition of DCs and T cells have 
been observed in psoriasis, a common cytokine-driven focal inflammatory skin disease. In 
this thesis we explore the functional profile of epidermal and dermal DCs and T cells in 
different phases of psoriasis, and how different cytokines present in homeostasis and 
inflammation affect the development of tissue resident memory T (Trm) cells.  
PAPER I: In lesional psoriasis, langerin- DCs accumulated in the epidermis. Both Langerhans 
cells (LCs) and epidermal DCs (eDCs) displayed upregulated pro-inflammatory genes and 
produced IL-23 after stimulation with ligands binding to toll-like receptor (TLR) 4 or 7/8. 
Elevated gene expression of IL23A and IL15 in LCs combined with their capacity to produce 
IL-23 upon TLR 7/8 stimulation suggested that LCs maintained their pro-inflammatory 
profile in resolved psoriasis.  
PAPER II: Granzymes (Gzms) and perforin are produced by cytotoxic T cells. Here we show 
that epidermal T cells produced GzmA in absence of perforin within psoriatic lesions. IL-17- 
stimulated human keratinocytes, in presence of GzmA, upregulated the production of 
CXCL1, CXCL12 and CCL4, involved in neutrophil and lymphocyte recruitment, therefore 
highlighting a new pathway of T cell driven recruitment of immune cells. 
PAPER III: In resolved psoriasis, epidermal resident T cells and LCs maintain a pronounced 
pro-inflammatory profile, whereas dermal T cells are less inflammatory. We observed an 
enrichment in the expression of the regulatory molecules FOXP3, CTLA4 and PD1 in T cells, 
and an increased IDO1 expression and IL-10 production by DCs. Clusters of Foxp3+ T cells 
and DCs were identified in the skin of UVB treated patients, hinting at a possible interaction 
between regulatory T cells and tolerogenic DCs in the dermis of resolved psoriatic lesions. 
PAPER IV: Healthy epidermis and dermis harbour phenotypically distinct subsets of Trm 
cells. Here we focused on the phenotypic and functional plasticity of skin CD8 Trm cells. 
Dermal Trm cells, mainly CD69+CD103-CD49a-, upregulated CD103 or both CD103 and 
CD49a after stimulation with TGF-b, IL-2 and IL-15. TCR engagement increased the 
proportion of CD103+CD49a+ cells. Conversely, epidermal Trm cells exposed to the same 
conditions did not change their phenotype, but their functional profile was affected by IL-17 
polarising cytokines. 
Collectively, these studies highlight the high pro-inflammatory potential of epidermal DCs 
and T cells during different phases of psoriasis. In contrast, dermal cells acquire tolerogenic 
features in resolved disease. Moreover, we show that the functionality of Trm cells is affected 
by their surrounding milieu. These results encourage to take compartmental immune 
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1 INTRODUCTION 
Our skin is the most important interface with the external environment, as it is both part of the 
image we provide to the society and forms an important biological barrier. As such, suffering 
from skin diseases is associated with unique challenges that bring together the discomfort 
provoked by the disease itself and a considerable psychological burden due to issues in 
coping with the body image. 
This thesis is an attempt to get a better understanding of the pathomechanisms of psoriasis 
and its key players within human skin. To achieve this, a high-resolution approach was 
employed by characterising dendritic cells and T cells from epidermis and dermis as separate 
entities, instead of analysing pooled cells in full thickness skin. Moreover, I decided not to 
distance myself from human immunology, despite the many limitations. Hopefully, a better 
understanding of the functional shades of dendritic cells and T cells from the two skin 
compartments would lead, one day, to the development of targeted therapeutical strategies for 
all the patients. 
1.1 THE SKIN  
The outermost barrier of the body, the skin, is a complex structure where multiple cell types 
cooperate to ensure the maintenance of the body temperature and hydric balance, the 
synthesis of vitamin D and the protection against external agents. The complexity of the skin 
is evident in its structural organisation containing three distinct anatomical compartments. 
Epidermis, dermis and hypodermis are connected by different types of skin-associated 
appendages, such as hair follicles, sebaceous glands and sweat glands. The epidermis is the 
outermost layer of the skin and is exposed to the external environment. The main cellular 
components of the epidermis are keratinocytes, actively proliferating in the stratum basale, 
the lowest part of the epidermis, and progressively differentiating until they complete their 
maturation into corneocytes in the stratum corneum, the apical part of the epidermis. Distinct 
subtypes of the keratinocyte-derived protein Keratin are expressed in the stratum basale, 
spinosum, granulosum and corneum, facilitating visualisation of altered keratinocyte 
differentiation in skin diseases. Once in the stratum corneum, the keratinocytes/corneocytes 
have lost the nucleus and the internal organelles and form a tight barrier that impedes the loss 
of water and forms a physical obstacle to the entrance of pathogens. The corneocytes persist 
in the stratum corneum for about 20 days (Wilhelm et al., 1990) before shedding off. The 
epidermis additionally contains a small population of melanocytes within the basement 
membrane, whose main function is to produce melanin. Melanin absorbs UV radiations  and 
is delivered to keratinocytes to protect their nuclei from UV damage (Kanitakis, 2002).  
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The dermis is situated below the epidermis and is mainly composed by connective tissue 
made of collagen and elastin, both components produced by skin fibroblasts. The dermis 
harbours a variety of anatomical structures interacting with the rest of the body. Blood and 
lymph vessels in the dermis act as gateways for cell trafficking to and from the skin. Nerve 
endings reach the dermis and the epidermis and transmit a wide range of perception of stimuli 
coming from the external environment. Sweat and sebaceous glands, as well as the innermost 
part of the hair follicle, are also located in the dermis and serve the important function of 
regulating the body temperature (figure 1.1). The skin is one site of Vitamin D synthesis and 
thus also acts as an endocrine organ. As the first interface with the external environment, 
several immune cells inhabit the skin in healthy conditions: dendritic cells (DCs), Langerhans 
cells (LCs), macrophages, T cells and mast cells are the main components of the innate and 
adaptive immune system that reside in the skin. Moreover, additional cell types such as 
neutrophils and blood derived T cells and DCs infiltrate the skin during inflammation. 
Resident non-immune cells such as keratinocytes and fibroblasts participate in the immune 
defence mechanisms by secreting pro-inflammatory and immune cell recruiting factors in 
case of infection or inflammation. 
 
As functional studies on immune cells are mainly performed in mice, it is important to 
understand the structural and cellular differences existing between the two species. Mouse 
skin is densely covered in fur and the epidermis is composed of fewer layers compared to 
human skin. On the contrary, human skin has a larger interfollicular area and is thicker 
compared to mouse skin. LCs are the sole professional antigen presenting cells present in 
both mouse and human epidermis, whereas the dermis of mice and humans contains two 
distinct populations of dermal DCs (Segura, 2016). Although the markers used to describe 
DCs are not the same between the two species, their functional profile are comparable, as will 
be described in more detail further on in this thesis. The most strikingly difference in the 
immune cell composition of the skin of mice and humans can be found in the T cell 
compartment. The skin of mice bred in research facilities contains mainly gd T cells and gd+ 










Figure 1.1. The skin structure 
and its components. 
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human epidermis does not contain DETCs (Pasparakis et al., 2014). These observations have 
important implications when establishing mouse models of skin diseases, as the basis of the 
pathological immune mechanisms in mouse skin inflammation does not necessarily reflect 
what happens in human skin, as will be discussed later for psoriasis. 
As the very first interface towards the external environment, keratinocytes actively participate 
to the skin immune defence by sensing the presence of pathogen associated molecular 
patterns (PAMPs) through Toll-like receptors (TLRs). TLRs are invariant receptors sensing 
structurally conserved molecules present on pathogens (Ermertcan et al., 2011, Medzhitov, 
2001). Keratinocytes express a wide range of surface and intracellular TLRs (Kollisch et al., 
2005, Miller, 2008, Nestle et al., 2009), that make them capable of alerting the immune 
system and initiate the inflammatory process after bacterial or viral challenge. As a 
consequence of TLR activation, keratinocytes produce pro-inflammatory cytokines and 
chemokines whose type, magnitude and kinetics depend on the type of TLR stimulation 
received by keratinocytes (Lebre et al., 2007). Keratinocytes are the main producers of anti-
microbial peptides (AMPs) in the skin, that fight bacterial infections by interfering with the 
bacterial cell wall (Zhang and Gallo, 2016). The production of AMPs by keratinocytes is an 
interesting example of the bilateral communication between epidermal immune and non-
immune cells. Induction of several AMPs belonging to the S100 family is mediated by T cell 
derived IL-17 and IL-22 (Liang et al., 2006). On the other side, the AMPs beta defensins 
serve a chemoattractant for T cells and DCs (Yang et al., 1999) and monocytes (Rohrl et al., 
2010). Moreover, beta defensins stimulate keratinocytes to produce chemoattractant for 
lymphocytes and monocytes (Niyonsaba et al., 2007),  and induce the expression of 
maturation markers in blood DCs (Funderburg et al., 2007) and in LCs generated from 
peripheral blood (Ferris et al., 2013). Similarly to defensins, the AMP LL-37 modulates 
chemokine production in keratinocytes (Chen et al., 2013, Nijnik et al., 2012) and induces 
DC maturation (Davidson et al., 2004), exemplifying the ongoing cross-talk between 
keratinocytes and immune cells. 
1.2 LANGERHANS CELLS: THE OUTPOST OF THE SKIN IMMUNE 
DEFENCE 
1.2.1 Langerhans cell ontogeny 
Langerhans cells reside in the outermost layer of the skin and pierce through keratinocytes’ 
tight junctions with their dendrites to scout the skin surface and sense the antigens that 
penetrated into the stratum corneum (Kubo et al., 2009). In homeostasis, LCs are the sole 
professional antigen presenting cells (APCs) within the epidermis and are second to 
keratinocytes in terms of cellular frequency (Kanitakis, 2002, Kashem et al., 2017, Merad et 
al., 2008). LCs have a peculiar ontogeny compared to the other populations of skin resident 
DCs. LCs are seeded in the epidermis during embryonic development (Collin and Milne, 
2016, Merad et al., 2008) and their local development within the skin depends on IL-34, 
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ligand of CFS-1R produced by epidermal keratinocytes (Wang and Colonna, 2014, Wang et 
al., 2012). Extensive studies in multiple experimental settings also showed that LCs self-
renew throughout life within the epidermis, contrary to the dermal DC population that is 
constantly replenished by circulating precursors. The clear demonstration of the self-renewal 
capacity of LCs came from research performed by Merad and colleagues: lethally irradiated 
mice, where all LCs and DCs are depleted, maintain host-derived LCs following 
reconstitution with congenital bone marrow cells. On the contrary, DCs in the spleen, liver 
and kidney are replaced by donor-derived cells (Merad et al., 2008, Merad et al., 2002). 
Further experiments based on parabiotic mice performed by the same authors reached the 
same conclusions (Merad et al., 2002). Interestingly, the same study also showed that CCR2+ 
LCs of donor origin successfully colonised the epidermis after UV exposure and were present 
in the skin for at least 12 weeks (Merad et al., 2002). Further studies in mice confirmed that 
the strong damage produced by HSV infection or UV irradiation causes LC depletion and 
replenishment of the epidermal LC pool by monocytes (Eidsmo et al., 2009, Ginhoux et al., 
2006, Sere et al., 2012), transiently infiltrating the skin, and subsequently by bone marrow 
precursors (Sere et al., 2012). 
Clever observations on transplanted patients, based on HLA mismatch between donor and 
recipient, seemed to confirm the longevity of LCs in a human setting. By following one 
patient after hand transplantation over a period of time reaching 10 years from the transplant, 
it has been shown that epidermal LCs remained of donor origin and were not replaced by 
cells of recipient origin (Kanitakis et al., 2011, Kanitakis et al., 2004) but the evidence on the 
dynamics of LC replenishment after an inflammatory insult in humans is so far lacking.  
1.2.2 TGF-b in LC physiology 
TGF-b appears to be one of the master cytokines in the regulation of LC physiology reflected 
by the complete absence of LCs in the skin of the TGF-b1 null mice (TGF-b1-/-) (Borkowski 
et al., 1996, Borkowski et al., 1997). Furthermore, the epidermis of mice lacking the receptors 
TGF-bRII (Bobr et al., 2012, Kaplan et al., 2007) and TGF-bR1 (Kel et al., 2010) presents a 
severe loss of LCs. Kel et al presented the interesting observation that LCs in the skin of the 
TGF-bR1 mouse seed and expand in the epidermis in the first days of life, although in 
reduced numbers compared to the wild-type control. However, after this initial expansion, 
LCs cannot keep their residency in the absence of the functional TGF-bR1, and gradually 
disappear from the epidermis (Kel et al., 2010). These results suggest that TGF-b signalling 
plays a crucial role in ensuring the residency of LCs in the epidermis after the cells seed and 
expand at the beginning of life (Chorro et al., 2009, Schuster et al., 2009). Indeed, LCs in the 
absence of TGF-b or TGF-b receptor-signalling display an increased migratory potential by 
expressing CCR7 (Bobr et al., 2012, Kel et al., 2010). Of relevance is the role of 
keratinocytes in ensuring the residency of LCs by converting the latent form of TGF-b to the 
active form (Mohammed et al., 2016). It is difficult to explore whether these basic biologic 
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processes discovered in mouse hold true for the human species, but it has been shown that 
TGF-b production in embryonic skin precedes the acquisition of langerin and CD1a markers 
by epidermal HLA-DR+ cells (Schuster et al., 2009). Another hint comes from the 
observation that patients suffering from hypertension treated with losartan, known to 
diminish the levels of TGF-b (Bar-Klein et al., 2014, Campistol et al., 1999, Khalil et al., 
2000), display reduced numbers of LCs in the epidermis (Mohammed et al., 2016). In in vitro 
experimental settings, TGF-b has been used to differentiate LC-like cells from CD34+ 
circulating precursors from peripheral blood or cord blood, together with different 
combinations of GM-CSF, TNF-a and IL-4 (Geissmann et al., 1998, Jaksits et al., 1999, 
Strobl et al., 1996). The criteria used to discriminate LCs from DCs after stimulating CD34+ 
precursors are the presence of structures resembling Birbeck granules and the expression of 
langerin, CD1a and E-cadherin. By adding TGF-b to the stimulation cocktail, the cell yield of 
LCs vs DCs increases compared to the original cocktail comprising only GM-CSF and TNF-
a (Caux et al., 1992, Caux et al., 1996, Strunk et al., 1996). This observation also stresses the 
importance of TGF-b in relation to LCs.  
1.2.3 LC phenotype and in vitro models 
The expression of langerin (CD207) and the presence of Birbeck granules are the key factors 
that distinguish LCs from any other cell type in mice and humans (Birbeck et al., 1961, 
Kissenpfennig et al., 2005a, Mc Dermott et al., 2002, Reynolds and Haniffa, 2015, Valladeau 
et al., 2000). Human LCs also express high levels of the surface markers CD1a (Fithian et al., 
1981, Klareskog et al., 1977, Rowden et al., 1977) and EpCAM (Eisenwort et al., 2011, 
Gaiser et al., 2012). Despite this ample choice of surface markers to identify LCs in healthy 
conditions, it is important to bear in mind that marker expression may vary on both LCs and 
other DCs in inflammatory conditions, as shown in atopic eczema (Wollenberg et al., 1996). 
Through the years, experimental models to study human LC functionality have been 
developed and used: LCs differentiated from circulating precursors, migrated LCs from skin 
explants and freshly isolated cells after enzymatic treatment of the epidermis. Choosing the 
appropriate in vitro system for functional studies can be challenging, as each of these models 
display advantages and disadvantages, in particular in cell yield and responsiveness to 
stimulation. Cell yield is rarely an issue when working with blood derived cells and CD34+ 
circulating precursors can be differentiated into cells expressing high levels of CD1a and 
langerin, deceivingly identical to epidermal LCs (Geissmann et al., 1998, Jaksits et al., 1999, 
Strobl et al., 1996). However, these cells display a mature phenotype, with high expression of 
CD80 and CD86 (Caux et al., 1992, Klechevsky et al., 2008), high cross-presentation 
capacity (Klechevsky et al., 2008) and unresponsiveness to thymic stromal lymphoprotein 
(Nguyen et al., 2011), characteristics that functionally differentiate them from skin-derived 
LCs. Migrated cells obtained after short term culture of skin explants give acceptable cell-
yield of skin-derived LCs, but with a mature phenotype like blood-differentiated LCs 
(Klechevsky et al., 2008). The immature features of LCs obtained after enzymatic treatment 
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of the skin (de Witte et al., 2007, Fujita et al., 2009, Peiser et al., 2003, Pena-Cruz et al., 
2001) make them appropriate for studies on the changes that LCs undergo after stimulation or 
antigen encounter. However, enzymatic isolation of skin-LCs results in a low and even 
prohibiting number of cells recovered after the tissue digestion, especially when the intent is 
to examine the function of LCs obtained from patient material. LC-like cell lines also exist, 
mimicking both mouse and human LCs, although their usage is not as widespread as other 
LC in vitro models. The MUTZ-3 cell line is a cytokine-dependent cell line where cells 
acquire the expression of langerin and CD1a after culture with TGF-b. Transcriptomic 
analysis of MUTZ-3 LCs compared to LCs, blood-derived or skin-derived DCs and in vitro 
DCs (like monocyte-derived DCs) showed that they cluster together with skin DCs rather 
than with blood DCs, but their gene expression profile resembles more mature monocyte-
derived DCs rather than skin LCs (Harman et al., 2013). 
1.3 DERMAL DENDRITIC CELLS: SURVEILLANCE DEEP IN THE 
SKIN 
Two populations of conventional dermal (dDCs), distinct from pDCs, inhabit the dermis of 
mice and humans in the steady state. The discovery of conventional DCs is attributed to 
Ralph Steinman, that first described DCs in lymphoid organs (Steinman and Cohn, 1973), but 
only in the nineties these cells have been detected in the dermis (Lenz et al., 1993). Dermal 
DCs are defined by their expression of surface markers. The most numerous population is 
composed by CD1c+ DCs in human skin, whose mouse orthologue is the CD11b+ population. 
In humans, CD1c+ DCs also express CD1a, but at a lower level compared to LCs, and 
CD11c, although this marker does not uniquely define CD1c+ DCs since it’s also expressed 
by other monocytes (Collin et al., 2013) and CD141+ DCs (Haniffa et al., 2012). Human 
CD141+ DCs are a small subset of recently discovered DCs. They are better defined by their 
expression of XCR1, since CD141 is upregulated by other cell types in inflammatory 
conditions (Kashem et al., 2017). These DCs are the human orthologue of the murine 
CD103+langerin+ DCs. A small subset of langerin-expressing non-LCs has been identified in 
the dermis and across different organs and, interestingly, these cells are more related to 
CD1c+ DCs than to CD141+ DCs (Bennett, 2015, Bigley et al., 2015). A circulating 
counterpart of both CD1c+ and CD141+ DC subsets, expressing the same markers, can be 
identified in blood (Haniffa et al., 2015). Both human dDC populations develop from a 
common precursor present in bone marrow, blood and peripheral lymphoid organs and, as in 
mouse, their development requires the fms (feline McDonough sarcoma) like tyrosine kinase 
3 ligand (FLT3L) signalling through FLT3 (Breton et al., 2015, Lee et al., 2015). Differently 
from LCs, dDCs express a wide variety of TLRs (van der Aar et al., 2007), that make dDCs 
perfectly equipped to sense different types of pathogens penetrating the deeper layer of the 
skin. Similarly to LCs, the surface expression of CD1c and CD1a makes dDCs capable to 
present lipid antigens. 
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1.4 OTHER MYELOID CELLS INHABITING THE SKIN: 
MACROPHAGES AND MONOCYTES 
Macrophages are resident non-migratory cells present in mouse and human skin and can be 
distinguished from DCs by their autofluorescent properties at the flow cytometer, their 
adhesion properties when cultured in plastic wells and their surface expression of CD14 and 
FXIIIa (Haniffa et al., 2015). A seminal study on human dermal macrophages revealed that 
they are long lived cells with slow turnover rate, inferior to dDCs in activating naïve T cells 
but capable of activating memory T cells (Haniffa et al., 2009). Their non-migratory 
properties make skin macrophages distinguishable from CD14+ monocytes, also resident in 
the skin, but capable of migrating from ex vivo dermal explants. Previously considered a part 
of DC family with high MHC class II expression, migratory CD14+ cells have been shown to 
be phenotypically and transcriptionally closer to monocytes than to DCs (McGovern et al., 
2014).  
1.5 T CELLS AND T CELL MEMORY – AN OVERVIEW 
T cells, as part of the adaptive branch of the immune system, provide a tailored immune 
response in the event of an infection by a foreign antigen. CD4+ T cells, or T helper (Th) 
cells, contribute to the inflammatory process by secreting mediators that recall other immune 
cells to the site of infection, activate B and T cells or enhance the phagocytic activity of 
macrophages. CD8+ T cells have cytotoxic functions and kill infected cells after recognition 
mediated by MHC class I interaction with the T cell receptor. The killing of the target cell is a 
complex process that involves production of both granzymes (Gzms) and perforin by the 
cytotoxic T cell, release of these components in the immunological synapse formed between 
the T cell and the target cell, formation of pores on the membrane of the target cell mediated 
by perforin and entrance of Gzms inside the target cell (Barry and Bleackley, 2002). Gzms 
subsequently activate caspase-mediated death programs inside the infected cell, resulting in 
its killing (Barry and Bleackley, 2002). T cells also exert important regulatory functions by 
maintaining self-tolerance and suppressing the pro-inflammatory functions of DCs and other 
T cells. Regulatory T (Treg) cells are CD4+ T cells specialised in these regulatory functions 
(Josefowicz et al., 2012). The transcription factor Foxp3 is widely used to define Treg cells, 
although it is not possible to directly link Foxp3 to T cell suppression. Indeed, Foxp3+ “Treg” 
cells lacking immunosuppressive functions can be identified in some settings (Allan et al., 
2007, Tran et al., 2007). In addition, Treg cells can lose the expression of Foxp3 and become 
pro-inflammatory (Zhou et al., 2009). Treg cells mediate inhibition of the immune response 
by producing the anti-inflammatory cytokines TGF-b and IL-10 (Josefowicz et al., 2012).  
One peculiar function of the members of the adaptive immune system is the ability to 
generate a memory of previously encountered threats. This allows the body to quickly 
respond to secondary infection, therefore making the immune response more efficient. 
 8 
During the primary infection, naïve T cells receiving the activation signal differentiate to 
effector T cells. After the resolution of the inflammation, the vast majority of the effector 
cells dies, but a small fraction survives and becomes memory T cells. Central memory T 
(Tcm) cells and effector memory T (Tem) cells are found in the circulation. Tcm cells 
express the lymph node homing receptors CD62L and CCR7 and have a high proliferative 
capacity, whereas Tem do not express CD62L and CCR7, have a lower proliferative capacity 
but increased cytotoxic capacity (Mueller et al., 2013). More recently, the addition of 
CX3CR1 to the set of markers used to delineate memory T cell subsets revealed the existence 
of a population expressing intermediate levels of CX3CR1, as opposed to CX3CR1hi Tem 
cells and CX3CR1neg Tcm cells. This new population, called peripheral memory T (Tpm) 
cells, recirculates between blood and tissues and is responsible for the surveillance of 
peripheral organs (Gerlach et al., 2016). 
1.6 TISSUE RESIDENT MEMORY T (TRM) CELLS IN THE SKIN 
Tissue resident memory T (Trm) cells are additional members of the memory T cell family. 
They are non-migratory (Jiang et al., 2012), can survive for a long time in the tissue (Mackay 
et al., 2012) and confer superior protection in case of secondary infections (Gebhardt et al., 
2009). CD8+ Trm cells have been better characterised compared to CD4+ Trm cells. The 
work included in this thesis focuses on CD8+ Trm cells, thus the caption Trm cells will be 
used in this thesis to refer solely to the CD8+ T cell subset. Phenotypically, Trm cells are 
CD62L negative, express CD69 or co-express CD69 and CD103 (Gebhardt et al., 2009, 
Masopust et al., 2006, Mueller and Mackay, 2016). CD69 is an inhibitor of the sphingosine-
1-phosphate receptor, used by T cells to follow the sphingosine-1-phosphate gradient towards 
the blood stream (Mackay et al., 2015), whereas CD103 binds to E-cadherin, abundantly 
present in epithelial surfaces (Cepek et al., 1994, Pauls et al., 2001). Another Trm cell marker 
is CD49a, the ligand for collagen IV present in the basement membrane separating epidermis 
and dermis (Gebhardt et al., 2009). Although Trm cells are most commonly defined by the 
expression of CD69, CD69- cells can be sorted from different human tissues. The 
transcriptional profile of tissue resident CD69- cells shows that they are more similar to the 
blood CD69- counterpart, whereas CD69+ Trm cells have a distinct transcriptional profile 
(Kumar et al., 2017). 
Studies on congenically transferred CD69-/- or CD103-/- cells in mouse showed that T cells 
lacking CD69 or CD103 have a lower capacity to be retained in the skin, therefore CD69 and 
CD103 have an important role in retaining the cells into the tissue (Mackay et al., 2013). 
Similarly to what has been shown for LCs, TGF-b collaborates with the cell surface markers 
to maintain Trm cell residency both in the skin and in the gut (Mohammed et al., 2016). 
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1.6.1 Development of skin Trm cells 
The development of skin Trm cells has been well-characterised in mice. Killer cell lectin-like 
receptor subfamily G1 (KLRG1) negative precursors entering the skin sequentially express 
CD69 and CD103 and give rise to Trm cells. The CXCR3-dependent infiltration in the 
epidermis exposes the cells to a cytokine-rich environment, in particular to TGF-b and IL-15, 
critical factors in the induction of CD69 and CD103 expression (Mackay et al., 2013). This 
mechanism is not skin specific, as the formation of Trm cells in other tissues such as gut 
(Sheridan et al., 2014, Zhang and Bevan, 2013) and lungs (Laidlaw et al., 2014) requires the 
same set of cytokines. One source of IL-15 in the skin has been identified in the keratinocytes 
forming the hair follicle, and the hair follicle itself is thought to be the entry portal for T cells 
in the epidermis in mouse skin (Adachi et al., 2015). Similar observations are yet to be made 
in human skin, but the morphological differences between mouse and human skin might lead 
to divergent conclusions than what has been observed in mice. Whereas Trm cells in the skin 
(Mackay et al., 2012) and gut (Casey et al., 2012) do not need the antigen stimulation for the 
upregulation of CD103, an antigen is required for the induction of CD103 expression in the 
brain (Wakim et al., 2010)  and in the lungs (Lee et al., 2011, McMaster et al., 2018).  
Trm cells slowly scout the epidermis in search of foreign antigens (Gebhardt et al., 2011) 
and, in case of secondary infections, they decrease their speed to proliferate in an antigen-
specific way (Beura et al., 2018, Park et al., 2018). In viral infections, recent data 
convincingly show that Trm cells proliferate in situ (Beura et al., 2018, Park et al., 2018). 
Additionally, newly formed Trm cells are established in the epidermis and share the 
epidermal niche with previously formed Trm cells (Park et al., 2018). In inflammation, other 
T cells with different TCR specificity can be recruited to the challenged site (Schenkel et al., 
2013). Very recent reports show that some of these non-specific recruited cells also 
upregulate tissue resident markers and are detected in the tissue long after the resolution of 
the inflammation (Beura et al., 2018, Park et al., 2018).   
1.6.2 Human skin Trm cells  
A high number of T cells reside in the adult human skin in the steady state (Clark et al., 
2006). The majority of T cells extracted from skin specimens express the cutaneous 
lymphocyte-associated antigen (CLA), that is also expressed on blood T cells with skin 
tropism (Fuhlbrigge et al., 1997). Skin resident T cells are most likely established in the skin 
as a result of repeated immunological challenges, since embryonic and foetal skin contain 
less T cells compared to adult skin (Schuster et al., 2012). As already mentioned, human Trm 
cells express CD69 and CD103 (Cheuk et al., 2017, Watanabe, 2015). Differences in the 
expression pattern of these markers exist in the two skin compartments: most of the 
epidermal CD69+ cells co-express CD103, whereas dermal Trm cells are mainly CD69 single 
positive (Cheuk et al., 2017). Additionally, CD49a is unevenly distributed on skin Trm cells, 
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being almost exclusively expressed in a subpopulation of CD69+CD103+ Trm cells in the 
epidermis (Cheuk et al., 2017). Little evidence is available on the developmental pathway of 
human Trm cells, except that TGF-b is important for the upregulation of CD103 on T cells 
derived from peripheral blood (Watanabe, 2015). 
1.6.3 Regulatory skin T cells 
In mice, Treg cells are established in the skin within the first days of life (Scharschmidt et al., 
2015), and both skin microbes and the development of the hair follicle promote the 
establishment of Treg cells in the skin (Scharschmidt et al., 2017). Treg cells reside in human 
skin, mainly in the dermis (Clark and Kupper, 2007, Sanchez Rodriguez et al., 2014), in close 
proximity to the hair follicle (Sanchez Rodriguez et al., 2014). They are present in the skin in 
a higher proportion compared to the circulating counterpart, and they accumulate in the skin 
over time as foetal skin has a lower frequency of Trm cells (Sanchez Rodriguez et al., 2014). 
Recently, the concept of “memory” was extended to the Treg cell family, and there are few 
indications obtained from murine models of inflammation that Treg cells possess memory-
like properties (Ali and Rosenblum, 2017, van der Veeken et al., 2016). It was shown that 
human skin Treg cells express CD45RO, commonly present on memory T cells, but at the 
moment this is the only clue on the existence of tissue resident memory Treg cells in humans 
(Sanchez Rodriguez et al., 2014). Further studies in the field might elucidate if Treg cells 
persist at the site of inflammation and their reaction to multiple inflammatory challenges. 
This information will be extremely valuable to understand the dynamics of recurrent 
inflammatory diseases and to find strategies to dampen the inflammation or prolong the time 
in remission via Treg cell modulation. 
1.7 FUNCTIONALITY OF SKIN RESIDENT IMMUNE CELLS 
1.7.1 Immune regulation and non-classical T cell activation by LCs 
It is a difficult task to summarise published data on LC-functionality in a few unifying 
concepts. As it is often the case, a wealth of reports on the function of LCs comes from 
murine models, while human immunology lags behind. Functional studies in mouse are 
possible thanks to the existence of models based on the use of the diphtheria toxin (DT) to 
ablate LCs. These models are knock-in models where the high affinity human DT Receptor 
(DTR) is inserted into the mouse langerin gene (Bennett et al., 2005, Kissenpfennig et al., 
2005a, Kissenpfennig et al., 2005b). In this way, DT injection causes the ablation of all 
langerin-expressing cells. It is important to point out that LCs are not the only langerin-
expressing dendritic cells in mouse, but a subpopulation of dDCs also expresses langerin 
(Bursch et al., 2007, Ginhoux et al., 2007, Nagao et al., 2009, Poulin et al., 2007). However, 
these populations can be differentiated by taking advantage of the fact that LCs and dDCs 
repopulate the skin with different kinetics after ablation of all skin langerin-expressing cells 
with DT. Langerin+ DCs reappear in the dermis after few days following DT injection, 
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whereas it takes weeks for LCs to reappear in the epidermis. This discrepancy can be 
exploited to study the effect of a treatment/infection in presence or absence of these two 
distinct cell populations. Moreover, langerin+ dDCs express CD103, whereas LCs lack this 
marker, and currently CD103 is preferentially used to describe this subset of dDCs, instead of 
langerin. A second murine model based on DT introduces human langerin regulated by DT 
subunit A (DTA) in mice, that results in the complete absence of epidermal LCs, whereas the 
dermal langerin+ dDCs are still present (Bursch et al., 2007, Kaplan et al., 2005, Romani et 
al., 2010). These two murine models, together with the discovery of DCs residing in the 
dermis in human and mouse (Lenz et al., 1993), were fundamental to give new impulse to LC 
research, by challenging the view of LCs as the stereotype of the immunogenic DCs that 
sense the antigen and migrate to the lymph node to elicit the immune response (Allan et al., 
2003, Romani et al., 2012, Romani et al., 2010). With the aid of the LC ablation models, it 
was possible to assign a specific function to epidermal LCs and dermal DCs and it was 
discovered that in some settings, and contrary to the common knowledge, dDCs have a 
prominent role in inflammation, whereas LCs were found to be dispensable (Kissenpfennig et 
al., 2005b) if not tolerogenic (Kaplan et al., 2005). Aside from these studies on lymph node 
migration and presentation to T cells mediated by the MHC class II machinery, LCs might 
have some sort of niche function strongly related to their unique phenotypic features. For 
example, the high expression of the lipid antigen presenting molecule CD1a (Van Rhijn et al., 
2015) could confer LCs superior antigen presenting abilities compared to dDCs. A murine 
model in which LCs express the human CD1a molecule proved that the lipid antigen 
urushiol, that causes severe dermatitis after the contact with urshiol-producing plants like the 
poison ivy, is presented to CD1a-reactive T cells and leads to the production of IL-17, and in 
the imiquimod model of psoriasis, self-lipid antigens presented to T cells by CD1a elicit IL-
17 production by T cells (Kim et al., 2016). In humans, a pioneer study showed that LCs 
present lipid antigens from Mycobacterium leprae to T cells (Hunger et al., 2004) and another 
report showed that CD1a-reactive T cells are present in human skin and can produce IL-22 
upon activation (de Jong et al., 2010). Other than the high expression of CD1a, LCs are 
associated with the unique presence of langerin and the organelles Birbeck granules. The 
function of these organelles has been enigmatic for a long time, but recent insights show that 
Birbeck granules are subdomains of the endocytic recycling compartment (Mc Dermott et al., 
2002). Interestingly, langerin can recognise microbial structures, such as the glycoprotein 
gp120 on HIV, internalise them and lead them to the Birbeck granules where they are 
degraded, therefore conferring LCs a protective role in case of HIV infection (de Witte et al., 
2007, van der Vlist and Geijtenbeek, 2010).  
TLR activation is one of the ways to study LC functionality. Skin LCs express a lower 
variety of TLRs (Renn et al., 2006, Takeuchi et al., 2003, van der Aar et al., 2007) (table 
1.7.1). Allogenic co-cultures of LCs differentiated from blood CD34+ precursors and T cells 
show that TLR-stimulated LCs can induce Th17 differentiation and IL-17 production, and 
that blocking TGF-b, IL-23 and IL-6 derived from LCs impairs the differentiation of Th17 
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cells (Aliahmadi et al., 2009). A similar study with the same setup showed that differentiated 
LCs induce Th17 polarisation specifically in the memory T cell subset (Duraisingham et al., 
2009).  
TLR Ligand Ligand species Location LCs dDCs 
TLR1 Triacyl lipopeptide Bacteria Cell surface Yes Yes 
TLR2 Zymosan Fungi Cell surface No Yes 
TLR3 Double stranded RNA Viruses Intracellular Yes Yes 
TLR4 Lipopolysaccharide (LPS) Bacteria Cell surface No Yes 
TLR5 Flagellin Bacteria Cell surface No Yes 
TLR6 Mycoplasma lipopeptide Mycoplasma Cell surface Yes Yes 
TLR7 Single stranded RNA Viruses, endogenous Intracellular Yes Yes 
TLR8 Single stranded RNA Viruses, endogenous Intracellular No Yes 
TLR9 Unmethylated CpG DNA Bacteria, viruses, endogenous Intracellular No No 
 
The efficacy of LCs in stimulating CD4+ T cells to release IL-17 was shown also by co-
culturing LCs migrated out of skin explants with allogenic T cells (Aliahmadi et al., 2009, 
Mathers et al., 2009). In the same manner, sorted LCs obtained after enzymatic digestion of 
the epidermis induced proliferation and IL-22 production in co-cultured allogenic T cells in 
both CD8+ and CD4+ T cells. The same effect was obtained after co-culturing dDCs and T 
cells (Fujita et al., 2009). A completely opposite outcome has been obtained by co-culturing 
skin LCs with autologous skin T cells: Foxp3+ Treg cells are the T cell subset proliferating in 
this setup (Seneschal et al., 2012). A precedent study reported the capacity of vitamin D3-
primed skin LCs in inducing Foxp3+ Treg cells with a mechanism mediated by TGF-b (van 
der Aar et al., 2011). This evidence gathered by studying skin derived LCs, together with the 
lack of different TLRs sensing bacterial antigens on the LC cell surface (van der Aar et al., 
2007), advocates for a physiologic role of LCs in maintaining tolerance within the skin. LCs 
derived from CD34+ blood precursors seem to be capable to cross-present antigens 
Table 1.7.1. TLR ligands and expression on skin LCs and dDCs (Ermertcan et al., 2011, Medzhitov, 
2001, van der Aar et al., 2007). 
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(Klechevsky et al., 2010, Ratzinger et al., 2004), but this is probably not the case for skin 
isolated LCs (Haniffa et al., 2012, Igyarto and Kaplan, 2013, van der Vlist et al., 2011). 
These results highlight that the model used to study LCs can greatly influence the results, 
especially in human studies, and phenotypical differences between LCs generated from 
CD34+ precursors, migrated from skin explants or isolated after enzymatic treatment of the 
epidermis might translate to functional dissimilarities. When approaching the literature on 
this subject, these aspects are essential to be kept in mind.  
1.7.2 Pro-inflammatory role of dermal DCs in inflammation and infection 
In inflammation, additional populations of DCs are recruited into the skin and the distribution 
of the surface markers across the DC subsets changes, thus it is difficult to study the 
contribution of single populations of resident or infiltrating DCs in inflammation (Haniffa et 
al., 2015). The first observation on the massive infiltration of DCs in peripheral tissues by 
inflammatory DCs was obtained in a model of Listeria monocytogenes infection, where 
monocytes accumulated in infected spleens, developed into DCs that produced TNF and 
inducible nitric oxide synthase (iNOS), therefore were called TNF iNOS producing (Tip)-
DCs (Serbina et al., 2003). In humans, infiltration of DCs in the skin during active 
inflammatory skin diseases has been noted both in atopic dermatitis and in psoriasis, but it is 
difficult to establish the origin and fate of these cells because of the inability to track human 
cells and to follow the disease evolution from the early phase to the resolution. Dermal DCs 
excel in the capacity to stimulate T cells: they engage the CD3 receptor by presenting the 
processed antigen on their MHC molecules (signal 1), they can upregulate CD80 and CD86 
expression (signal 2) and produce cytokines upon activation (signal 3). Both CD1c+ and 
CD141+ DC subsets are migratory. The functional difference between the two DC 
populations, both in mice and in humans, stems from their ability to elicit a response from 
CD4+ or CD8+ T cells. CD1c+ DCs, in mouse and in humans, are superior in eliciting a CD4 
T cell response and produce a set of cytokines capable of inducing Th1, Th2 and Th17 
subsets depending on the type of antigen encountered (Kashem et al., 2017). Conversely, 
murine CD103+ DCs and their human orthologue CD141+ DCs, of more recent discovery, are 
superior in cross-presentation to CD8+ T cells (Bedoui et al., 2009, del Rio et al., 2010, 
Haniffa et al., 2012). 
1.7.3 Dermal DCs and tolerance  
Numerous evidence points towards the involvement of DCs in tolerogenesis. At a central 
level, DCs contribute to the establishment of immune tolerance (Bonasio et al., 2006, Brocker 
et al., 1997, Manicassamy and Pulendran, 2011, Proietto et al., 2008, Watanabe et al., 2005). 
At a peripheral level, mature IL-10 producing pulmonary DCs maintain tolerance in murine 
lungs (Akbari et al., 2001) and, in the gut, CD103+ DCs promote Treg cell formation 
(Matteoli et al., 2010, Russler-Germain et al., 2017, Siddiqui and Powrie, 2008). In human 
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foetal development, foetal DCs seem to promote tolerogenesis by inhibiting T cell release of 
pro-inflammatory cytokines and induce differentiation of Treg cells (McGovern et al., 2017). 
In vitro, human blood-derived DCs, displaying an immature phenotype with low expression 
of CD80, CD83 and CD86, have a poor capacity to stimulate T cell proliferation and 
preferentially generate IL-10 producing T cells instead (Dhodapkar et al., 2001, Jonuleit et 
al., 2000). How dDCs contribute to the tolerance in the skin has not been clearly elucidated, 
especially regarding human dDCs. However, one report identifies CD141+ dDCs as IL-10 
producer cells capable of inducing T cells with some Treg cell phenotype features (Chu et al., 
2012). Another report instead compares skin-derived vitamin D3-primed LCs and dDCs in 
their ability to induce a tolerogenic phenotype in co-cultured allogenic T cells (van der Aar et 
al., 2011). Vitamin D3 as a stimulant has been chosen because of its known 
immunosuppressive properties, especially concerning DCs (Anderson et al., 2009, Arnson et 
al., 2007, Berer et al., 2000, Griffin et al., 2001, Griffin et al., 2000, Penna and Adorini, 2000, 
Piemonti et al., 2000). The investigators show that vitamin D3-primed LCs induce the 
expression of CD25 and Foxp3 in co-cultured T cells, but these cells are not able to produce 
IL-10. On the contrary, T cells derived from vitamin D3-stimulated dDC co-cultures do not 
express Foxp3 but are functionally tolerogenic, being capable of producing IL-10. Moreover, 
an interesting piece of data in the study is that LCs and dDCs achieve the induction of 
tolerogenic T cells through the secretion of different mediators, namely TGF-b for LCs and 
IL-10 for dDCs (van der Aar et al., 2011).  
In active inflammation, immunosuppressive mechanisms are activated together with the pro-
inflammatory program to control extensive inflammation. One of these regulatory 
mechanisms is driven by the enzyme indoleamine 2,3-dioxygenase 1 (IDO1). IDO1 is the 
first enzyme in the tryptophan degradation pathway and, as such, acts as a limiting factor in 
the degradation of the essential amino acid tryptophan to kynurenine. IDO1 expression is 
upregulated in DCs by pro-inflammatory molecules, especially IFN-g, but it’s also induced 
by the interaction of CD80/CD86 on DCs with the cytotoxic T lymphocyte antigen 4 (CTLA-
4) (Cederbom et al., 2000, Fallarino et al., 2003, Grohmann et al., 2002, Mellor et al., 2003, 
Mellor and Munn, 2004). The depletion of tryptophan by the IDO1 pathway causes inhibition 
of T cell proliferation and cell cycle arrest because the cells are deprived of one amino acid 
essential for protein synthesis (Hwu et al., 2000, Munn et al., 1999). Moreover, toxic effects 
on T cells by the metabolites generated after tryptophan degradation have been reported 
(Fallarino et al., 2002, Hayashi et al., 2007, Moffett and Namboodiri, 2003). Conversely, 
these metabolites are also involved in the expansion of Treg cells (Baban et al., 2009, Hill et 
al., 2007). Overall, these mechanisms triggered by reduction in tryptophan result in 
immunosuppression (figure 1.7.1).  
IDO1 is upregulated in inflammatory skin diseases, including psoriasis (Harden et al., 2016, 
Scheler et al., 2007). IDO1 has also been reported in different types of cancer, therefore 
finding ways to modulate the expression of IDO1 is particularly interesting in the field of 
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cancer immunology (Brochez et al., 2017) (figure 1.7.3). Tryptophan-mimetic compounds 
that bind to IDO1 and inhibit its activity, aiming at reverting the immunosuppression state 
that impedes the immune system to fight the tumour, are now in clinical trials (Brochez et al., 
2017, Prendergast et al., 2017). However, in the context of skin diseases, the opposite tactic 
aiming at increasing IDO1 activity would be beneficial to shut down the inflammation or to 




1.7.4 Human Trm cell function in skin diseases  
It is difficult to establish antigen specificity combined with functionality at single cell 
resolution in human T cells and the vast majority of the studies on Trm cell functionality 
focuses on cytokine production in the absence of defined antigen specificity, comparing 
healthy skin and diseased skin. Several skin conditions have been associated with pathogenic 
Trm cells, and these diseases all present with well-demarcated lesions in fixed spots on the 
skin. Fixed drug eruption, vitiligo and psoriasis are all examples of Trm cell associated skin 
diseases (Clark, 2015). Fixed drug eruption is a phenomenon that occurs on the skin after 
systemic administration of a drug, that spontaneously resolves after the interruption of the 
therapy but comes back in the same spot if the same drug is administered again (Shiohara, 
2009). CD8+ effector cells are implicated in the pathogenesis of fixed drug eruption, and 
CD8+ cells producing IFN-g have been identified in the epidermis of fixed drug eruption 
resting lesions (Teraki and Shiohara, 2003). Moreover, an enrichment of CD69+ and CD103+ 
T cells has been noted in the epidermis of patients with fixed drug eruptions, and these cells 
quickly upregulate IFNG expression (Mizukawa et al., 2002). Vitiligo is a skin disease 
characterised by local loss of melanocytes. T cell-mediated killing of melanocytes is one of 
the mechanisms responsible for the loss of pigment on fixed patches of the skin. Cytotoxic 
Trm cells are enriched in vitiligo lesions and are excellent producers of IFN-g and TNF, as 
demonstrated by two independent reports on the phenotype and functional profile of Trm 














Figure 1.7.3. IDO1 in the tryptophan metabolism and its expression in diseased conditions. (A) IDO1 
expression is increased by IFN-g and TNF. IDO1 transforms the tryptophan to kynurenine, with implications 
for the T cell response. (B) The T cell response is inhibited in cancer, where IDO1 is highly expressed. 
Inflammatory diseases would benefit from an increased IDO1 expression to contrast the T cell activation.   
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1.8 PSORIASIS 
Psoriasis is a common inflammatory skin disease affecting 2-3% of the world population. The 
most common psoriasis phenotype is plaque psoriasis, or psoriasis vulgaris, characterised by 
well-demarcated, red and scaly plaques on the skin. Other clinical variants of psoriasis 
include guttate psoriasis, where small lesions appear all over the body in association with 
streptococcal throat infections, inverse psoriasis that affects skin folds and is characterised by 
red shiny lesions lacking scales, pustular psoriasis with a massive influx of neutrophils into 
the epidermis, and erythrodermic psoriasis where a large portion of the skin is covered by 
psoriasis (Griffiths, 2004). Any part of the body can be affected and, depending on the 
percentage of the body surface involved, the disease severity is classified as mild (less than 
3% of the body surface involved), moderate (between 3 and 10% of the body surface 
involved) or severe (more than 10% of the body surface involved). The treatment options 
vary depending on the severity of the disease and on the body location. Psoriasis per se is not 
a life-threatening condition, but the disease affects the quality of life in several ways, from 
social isolation to employment problems (Kimball et al., 2005). Patients report problems in 
coping with the body image, the symptoms of the disease (itch on the site of the lesions) or 
the treatments’ side effects. The patients’ condition can worsen by the onset of common co-
morbidities, such as psoriatic arthritis, metabolic syndromes and depressive disorders (de 
Oliveira et al., 2015). Around 30% of the patients with psoriasis develop joint diseases, as 
reported in a study on more than 5000 psoriatic patients in the Nordic countries (Zachariae, 
2003). Metabolic syndrome, obesity, diabetes and heart failure are noted primarily in patients 
with severe psoriasis (Henseler and Christophers, 1995).  
1.8.1 Genetics 
Genetic predisposition plays a paramount role in the risk of developing psoriasis, as firstly 
demonstrated in studies involving monozygotic and dizygotic twins (Bowcock, 2005, Duffy 
et al., 1993, Farber et al., 1974). Many psoriasis-associated genes are related to 
immunological pathways. Some types of HLA genes, in particular HLA-Cw6, show a strong 
association with psoriasis. HLA-C is an MHC class I gene, it is therefore implicated in 
presentation of intracellular peptides to CD8+ T cells and NK cells. Other genes of more 
recent discovery, thanks to genome-wide association studies, establish a link between 
psoriasis and polymorphism of genes related to the MHC class I pathway (ERAP1), IL-23 
(IL12B, IL23A and IL23R), Th17 polarisation (STAT3) or NF-kB pathway (CARD14) 
(Harden et al., 2015b). The correlation of the psoriasis-associated genes with the immune 
system clearly enforces the view of psoriasis as a skin disease with a strong immune-related 
component. 
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1.8.2 Psoriasis pathogenesis and hallmarks of the disease 
One proposed pathogenic mechanism for the development of early lesions is based on the 
activation of pDCs by LL-37 and self DNA complexes, which leads to IFN-a production that 
consequently initiates the inflammatory cascade leading to profound epithelial alterations 
(Nestle, 2009, Nestle et al., 2005).  
Other proposed adaptive immune mechanisms are based on the presence of CD1a- or 
melanocyte- autoreactive T cells in the skin of psoriatic patients (Arakawa et al., 2015, 
Cheung et al., 2016). The inflammation in the skin causes acanthosis, parakeratosis, vessels 
alterations and infiltration of immune cells in the skin (Lin et al., 2011, Teunissen et al., 2014, 
Villanova et al., 2014) (figure 1.8.2).  
 
Recent drug development has highlighted the role of the IL-23/Th17 axis in the maintenance 
of psoriasis. Activation of Th17/Tc17 cells leads to the production of IL-17 which stimulates 
the release of pro-inflammatory cytokines and neutrophil-attracting chemokines from a 
variety of immune and epithelial cells. IL-17 itself acts as a potent recruiter and activator of 
neutrophils (Di Cesare et al., 2009), and neutrophils themselves are also proposed as a source 
of IL-17 in psoriasis (Lin et al., 2011). Th17/Tc17 cells can also produce IL-22. In contrast to 
IL-17, IL-22 does not act on immune cells but on epithelial cells, promoting proliferation and 
release of antimicrobial mediators (Wolk and Sabat, 2006), therefore it is evident how IL-17 
and IL-22 play a fundamental role in the generation of the hallmarks of the disease. One of 
the peculiarity of psoriasis is that the disease comes back in previously affected sites of the 
skin after successful treatment. This feature led investigators to suggest that a memory of the 
disease is maintained in cells residing in psoriatic-treated patches on the skin (Clark, 2011), 
indeed treated skin sites present residual alterations in immune and non-immune genes, even 
if the morphology of the skin is normalised, that has been named “molecular scar” (Cheuk et 
al., 2014, Matos et al., 2017, Suarez-Farinas et al., 2011). 
1.8.3 Current treatments 
The therapeutic decision in psoriasis depends on the severity of the disease and the location 
of the affected skin. Currently, the major clinical challenges are to induce long-term disease 
remission and to treat psoriasis in body areas that are particularly difficult to treat, such as the 
nails, the scalp and the genital area. Mild psoriasis is treated with topic application of 
corticosteroids alone or in combination with Vitamin D. For moderate to severe psoriasis, 
Figure 1.8.2. Histological 
features of plaque psoriasis. 
Healthy skin (left) and lesional 
psoriatic skin (right). Courtesy of 
Dr. Hedblad. 
 18 
systemic treatment with immunosuppressive agents, such as ultraviolet (UV) therapy or 
methotrexate, is widely used. Narrow-band UVB therapy reduces the inflammation by 
several mechanisms, including T cell apoptosis (Ozawa et al., 1999) and inhibition of 
cytokine production including IL-12 and IL-23 (Johnson-Huang et al., 2010, Piskin et al., 
2004). Despite UV rays causing skin cancer, studies on narrow-band UVB therapy used 
according to clinical guidelines show no increase in cancer risk (Lee et al., 2005). In contrast 
to UVB therapy, the exact mechanism of action of methotrexate is not fully understood, but 
this remains a safe and cheap treatment for moderate-to-severe psoriasis. Currently still a 
second or third line of treatment for severe disease, biologic therapy targeting TNF, IL-12/23 
or IL-17 has been introduced with astounding efficacy in relatively recent times. The term 
“biologics” refers to a class of protein (usually monoclonal antibodies) targeting pro-
inflammatory cytokines or cytokine receptors. Regarding the safety profile of biologics, it 
seems that these agents are well tolerated, even after long term therapy (Rustin, 2012). 
1.8.4 LCs in psoriasis  
LCs in active psoriasis are exposed to multiple environmental pro-inflammatory signals from 
keratinocytes and immune cells that can alter their function and their phenotype. TLRs on 
keratinocytes have an altered expression pattern in psoriasis (Miller, 2008), so it would not be 
surprising if the expression or activating threshold of TLRs would differ in LCs between 
healthy and psoriatic skin. Another potential environmental factor is the microbiome. Several 
investigations on the psoriasis microbiome have been conducted, but the results do not show 
drastic differences between healthy and psoriatic microbiome, as is the case with atopic 
dermatitis (Fahlen et al., 2012, Gao et al., 2008, Grice et al., 2009, Paulino et al., 2006, Tett et 
al., 2017).  
The challenge in enumerating LCs  in healthy and diseased skin has been documented since 
the end of the eighties, where a methodological article describing six different ways to count 
LCs showed profound differences in LCs in psoriasis compared to healthy skin depending on 
the method employed for counting (Bieber et al., 1988). Several publications report an 
increase (Baker et al., 1985, Fujita et al., 2011, Komine et al., 2007), a decrease (Bos et al., 
1983, Glitzner et al., 2014, Lisi, 1973) or a stable (Czernielewski et al., 1985, Gommans et 
al., 1987, Gunther et al., 2012, Guttman-Yassky et al., 2007) number of LCs in lesional 
psoriasis, compared to healthy skin, using different enumeration methods. The reasons for 
such contradicting results could lie in the cellular markers used for the enumeration and the 
location where the biopsies were collected within the plaque. Many authors used CD1a for 
the identification of LCs and report an increase in the number of cells within the lesional 
plaques. However, CD1a expression in active lesions is not a prerogative of LCs but is shared 
with a subpopulation of langerin- DCs infiltrating the epidermis. The presence of this 
additional population may contribute to increase the number of counted cells, unless an 
additional marker such as langerin is used for co-staining. Less, but more consistent data are 
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available on the number of LCs in perilesional skin during acute psoriasis, with several 
articles agreeing in reporting an increased number of LCs close to the border of the lesions 
(Alshenawy and Hasby, 2011, Gordon et al., 2005, Komine et al., 2007). In resolved skin, LC 
numbers have been reported to be reduced after psoralen and ultraviolet A (PUVA) treatment 
(Czernielewski et al., 1985, Erkin et al., 2007, Ree, 1982), and increased after biologics 
administration in resolved skin after treatment (Gordon et al., 2005, Hendriks et al., 2014) or 
uninvolved skin (Piaserico et al., 2013). Of relevance is the disappearance of the pro-
inflammatory infiltrating langerin- cells from the epidermis after treatment with biologics or 
narrow band UVB (Johnson-Huang et al., 2010, Lowes et al., 2005). 
Functional studies on human LCs in psoriasis are scarce but suggest an active role in 
sustaining the inflammation. Early reports show migrational impairment of LCs from non-
lesional skin of psoriasis patients in response to the administration of subcutaneous TNF and 
IL-1b correlating with the time of onset of the disease (Cumberbatch et al., 2006, Eaton et al., 
2014, Eaton et al., 2017, Shaw et al., 2010). Interestingly, a recent follow-up identified IL-17 
stimulated keratinocytes as the source of unidentified factors causing the migrational 
impairment of LCs (Eaton et al., 2017). LCs sorted from atopic dermatitis or psoriasis skin 
showed comparable abilities to stimulate T cells in an allogenic setup, but displayed some 
differences in the chemokine gene expression profile, as LCs from psoriasis skin expressed 
more CXCL1 and CXCL10, immune cell chemoattractants, and CCL18 and CCL20, 
important pro-inflammatory mediators (Fujita et al., 2011). Conversely, LCs from atopic 
dermatitis showed upregulation of CCL17, and collectively, these result show that LC profile 
is disease-specific, despite the similar ability to stimulate T cells in the artificial context of the 
mixed leucocyte reaction. More recently, LCs were found to produce IL-23 after stimulation 
with the TLR2 ligand zymosan (Sweeney et al., 2016). This finding is important for two 
reasons: one reason is that it attributes LCs the capacity to skew T cells towards a Th17/Tc17 
phenotype, the second reason is that it indirectly shows an altered TLR expression pattern on 
psoriatic LCs. The presence of a subset of LCs expressing CD5 has been recently reported in 
healthy skin, and increased frequency of this population is found in lesional psoriasis 
(Korenfeld et al., 2017). As already mentioned, LCs express high levels of CD1a, important 
for the presentation of lipid antigens. In psoriasis, CD1a-restricted T cells capable of 
producing IL-17 and IL-22 have been detected (Cheung et al., 2016) but, despite the existing 
premises for local antigen presentation and elicitation of the T cell response within the skin, 
the direct engagement of LCs and CD1a-restricted T cells in skin lesions has not been 
reported yet. Even more interesting is the understanding of the contribution of resident cells 
in disease flares. Resident T cells with high IL-23R expression persist in the skin of treated 
patients (Cheuk et al., 2014), and gene expression profile alterations persist in 
morphologically healed skin, thus raising the possibility that LCs could have a role in 




1.8.5 Dermal DCs in psoriasis  
The majority of studies on psoriatic DCs investigates CD11c+ cells in the dermal 
compartment. It is important to underline that, in humans, CD11c has been shown not to be 
an absolute marker for DCs but can be expressed by monocytes and neutrophils (Loike et al., 
1991, Maecker et al., 2012). Nevertheless, many studies, including ours, on active psoriasis 
use CD11c in combination with HLA-DR as a primary marker to define DCs, although 
markers such as CD14 and CD16 would help to distinguish monocytes and macrophages 
from DCs. Shortly after the discovery of IL-23 and the first studies on Th17 T cells, Lee and 
co-workers analysed IL23A mRNA expression of whole skin cell suspensions and found it 
upregulated in active psoriatic lesions. At that time, a good antibody for IL-23p19 staining 
was not available, so the group analysed the staining pattern of the common IL-12/IL-23 
subunit, p40, and found that this protein was mainly present in the dermis of psoriatic patients 
and a dendritic cell shape of the stained cells was observed (Lee et al., 2004).  This discovery 
led to a deeper effort to delineate the pro-inflammatory profile of dDCs. An increase in the 
number of CD11c+ cells is apparent in the dermis in active psoriasis (Guttman-Yassky et al., 
2007, Lowes et al., 2005, Zaba et al., 2009) but their clear phenotypic description is still 
lacking. These cells have been described in different ways (Tip-DCs or slan-DCs) but when it 
comes to their pro-inflammatory properties, they seem to be overlapping. Human TNF and 
iNOS producing (Tip-) DCs, as the related mouse population, produce TNF and iNOS and 
are considered non-resident because of the lack of CD1c and CD141 surface markers. It is a 
very heterogeneous population, with overlapping expression of CD163 (macrophage marker), 
DC-SIGN (immature DCs and macrophages) and CD14 (monocyte, DCs and macrophages) 
(Zaba et al., 2009). 6-sulfo LacNAc (Slan)-DCs have been originally described in blood 
(Schakel et al., 2002) and subsequently identified in inflamed skin (Hansel et al., 2011) as 
TNF and iNOS producer population. The blood slan-DCs express CXCR4 and the 
Figure 1.8.4. Interactions between Langerhans cells, T cells and keratinocytes in lesional psoriasis. 
Schematic representing the mediators involved in the cross-talk between cells in the epidermis of psoriatic 
lesions (Eidsmo and Martini, 2018).  
  21 
complement component 5a receptor (C5aR): their ligands, CXCL12 and C5a, are abundant in 
psoriasis skin and taken the presence of skin slan-DCs in proximity of the dermal blood 
vessels, the authors speculate that slan-DCs in skin directly come from the blood (Hansel et 
al., 2011). Regarding the functionality of Tip-DCs, a population of dermal CD11c+ non-
resident DCs, that includes Tip-DCs, emigrated from cultured biopsies showed the capacity 
to stimulate T cell proliferation and IL-17 and IFN-γ production in an alloreactive experiment 
(Zaba et al., 2009). Similar results have been achieved when culturing blood slan-DCs with 
allogenic T cells (Hansel et al., 2011). Taken together, the bulk of descriptive data and the 
few mechanistic studies in an alloreactive context suggest a prominent role for DCs, both 
resident and infiltrating, in sustaining the inflammation in active psoriasis.  
Psoriasis treatments seem to normalise the number of dDCs and reduce the infiltration of 
inflammatory DCs in the skin. UVB treatment, one of the first treatment options in the 
treatment of moderate-to-severe psoriasis, reduces the number of inflammatory DCs in the 
dermis in responding subjects, whereas inflammatory dDCs persist in non-responsive lesions. 
Anti-TNF (aTNF) treatment (Infliximab, an aTNF-antibody) reduced the expression of 
IL1B, IL12B and IFNG in skin after treatment and reduced the production of IL-12 and IL-23 
in blood derived slan-DCs from treated patients (Brunner et al., 2013). Another aTNF agent 
(Etanercept, soluble TNF receptor) gave analogue results on blood slan-DCs cytokine 
production but, interestingly, slan-DCs that remain in the skin retained the production of 
TNF-α in biopsies taken after 24 weeks of treatment (Gunther et al., 2013). Specific therapies 
against IL-23/IL-17, the major players in psoriasis pathogenesis, have been developed. Early 
studies on Ixekizumab (anti-IL-17 monoclonal antibody) showed a decrease of immune cell 
infiltration (both T cells and CD11c+ cells) and decreased IL17A, IL22, IL12B and IL23A 
gene expression after 6 weeks of treatment (Krueger et al., 2012). Two anti-IL-23 agents, 
Aprilimod (small molecule inhibiting the synthesis of IL-12 and IL-23) and Guselkumab 
(specific anti-IL-23 monoclonal antibody), ameliorated the clinical phenotype of the disease 
and inhibited the infiltration of immune cells in psoriatic skin (Sofen et al., 2014, Wada et al., 
2012). Therefore, the common denominator of successful therapies is the capacity to reduce 
the immune infiltration into the skin and to decrease the production of pro-inflammatory 
cytokines. 
1.8.6 T cells in psoriasis 
Evidence points towards a pathogenic role of T cells and Trm cells in psoriasis. Early studies 
showed that depleting T cells temporarily heals human psoriasis, proving the involvement of 
T cells in the psoriasis pathology (Prinz et al., 1991). In landmark experiments, non-lesional 
psoriatic skin was transplanted on immunodeficient mice and spontaneously gave rise to a 
psoriasis-like dermatitis. The administration of an anti-CD3 antibody prevented the 
exacerbation of the pathology, showing the central role of T cells in the development of 
psoriasis (Boyman et al., 2004). Overall, the number of T cells increases in the skin during 
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the disease flare (Boyman et al., 2004, Cheuk et al., 2014). The impressive response to 
biologic drugs targeting the IL-23/Th17 axis clearly shows the strong link between psoriasis 
and IL-17 (Di Cesare et al., 2009). T cells within psoriatic lesions are one of the sources of 
IL-17 and are also capable of producing IFN-g, IL-13 and IL-22 (Cheuk et al., 2017, Cheuk et 
al., 2014, Hijnen et al., 2013, Lowes et al., 2008). Interestingly, double-producing IFN-g and 
IL-17 cells are detected among Trm cells in lesional psoriasis, highlighting the strong 
inflammatory potential of Trm cells in active disease. These cells are absent in healthy skin or 
in vitiligo (Cheuk et al., 2017). A recent paper analysed the variety in the TCR repertoire and 
the clonality of skin T cells in full thickness skin from lesional and resolved psoriatic skin 
(Matos et al., 2017). Although the evidence that T cells in psoriasis are not monoclonal is not 
new (Harden et al., 2015a), the interesting finding from Matos and colleagues is the presence 
of psoriasis-specific T cell clones possessing similar TCR nucleotide sequences or giving rise 
to overlapping amino acid sequences, within the same individual or across different patients 
(Matos et al., 2017). With the fast development of current technologies (Dash et al., 2017, 
Glanville et al., 2017), the hope is that one day it will be possible to know what these 
“pathogenic” T cells recognise, with the scope of identifying one or multiple antigens 
responsible for triggering the aberrant immune response. CD1a-reactive T cells producing IL-
17 and IL-22 after activation have been identified in both non-lesional and lesional skin of 
patients with psoriasis (Cheung et al., 2016), and T cell clones specific for a melanocyte-
derived antigen were isolated from the skin of a psoriatic patient (Arakawa et al., 2015). 
Despite the challenges to verify to which extent these autoreactive T cells are found in a 
broader population of patients with psoriasis, these two papers open up to the existence of 
alternative models of psoriasis pathogenesis and disease maintenance. In resolved lesions, the 
number of epidermal and dermal T cells is dramatically reduced (Cheuk et al., 2014, Krueger 
et al., 2012, Lowes et al., 2005), but molecular alterations still persist despite the normalised 
skin morphology. T cells in resolved epidermis display a high expression of IL-23R and a 
higher proportion of cells produce or co-produce IL-17 and IL-22 after stimulation, compared 
to healthy epidermal T cells and regardless of the treatment method (UVB or biologics) 
(Cheuk et al., 2014). An interesting feature of T cells in resolved skin is that this high pro-
inflammatory potential concerns only T cells in the epidermis, but not T cells in the dermis 
whose pro-inflammatory profile is much milder compared to the epidermal counterpart, thus 
highlighting how different the cell behaviour is in the two compartments of the skin. Previous 
studies therefore highlight the need to examine dermal T cells in depth. 
1.8.7 Mouse models of psoriasis 
Despite the fact that psoriasis is a human disease and not naturally occurring in mice, murine 
models have been developed to unravel specific pathogenic roles for immune cell subsets and 
to test active compounds (Eidsmo and Martini, 2018). Early studies employed genetically 
modified mouse strains to recapitulate the skin phenotype of psoriasis, although some of the 
models fail to reproduce the infiltration of immune cells seen in human psoriasis (Gudjonsson 
et al., 2007, Schon et al., 2001, Sundberg et al., 1993). Currently, the most commonly used 
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mouse model of psoriasis is based on the application of the TLR7 agonist Imiquimod (IMQ) 
to induce a psoriasiform dermatitis. In the IMQ mouse model of psoriasis, the phenotypical 
features of the disease are reproduced, as well as the immune cell infiltration typical of 
human psoriasis (van der Fits et al., 2009). The number of T cells in the skin, of prominent gd 
phenotype, increases few days after the application of IMQ, and T cells are the source of IL-
17 driving the inflammation (Wohn et al., 2013, Yoshiki et al., 2014). LCs might be the 
source of IL-23 necessary to trigger IL-17 release from gd+ T cells (Sweeney et al., 2016, 
Xiao et al., 2017, Yoshiki et al., 2014), but another study ascribes this function to dDCs 
(Wohn et al., 2013). The number of DCs in the dermis is increased in the IMQ mouse model 
of psoriasis (Terhorst et al., 2015, van der Fits et al., 2009) as well as in the model based on 
IL-23 injection in the skin (Singh et al., 2016) or in the Junf/f JunBf/f K5creER (DKO*) mouse 
(Glitzner et al., 2014), and all these studies agree on their marked pro-inflammatory function. 
LCs have been found to have an immunomodulatory function in the DKO* mouse, where 
LCs display high IL10 expression and upregulate PD-L1 (Glitzner et al., 2014) , and when the 
application of IMQ is prolonged up to two weeks to mimic the chronicity of psoriasis 
(Terhorst et al., 2015). However, the study does not present data on which cytokines 
produced by LCs are responsible for this immunomodulatory function, nor what is the 
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2 AIMS 
This thesis aims at dissecting the phenotype and function of LCs, DCs and T cells in different 
anatomical skin compartments in different phases of psoriasis. 
Aims: 
• Characterise the functional profiles of LCs and eDCs in the epidermis of active and 
resolved psoriatic skin (PAPER I); 
 
• Explore the role of the pro-inflammatory T cell derived granzyme A in active 
psoriasis (PAPER II); 
 
• Examine the anti-inflammatory features of dermal DCs and T cells residing in the 
skin of successfully treated patients (PAPER III) and 
 
• Investigate the phenotypic and functional plasticity of epidermal and dermal Trm 
cells in healthy skin (PAPER IV).  
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3 MATERIALS AND METHODS 
 
3.1 TISSUE SAMPLES (PAPER I, II, III AND IV) 
Healthy skin from patients undergoing reconstructive surgery was obtained from Karolinska 
University hospital or from AdVita clinic (Stockholm, Sweden). Samples from lesional, non-
lesional or resolved psoriatic skin were collected from patients at Karolinska University 
hospital (Stockholm, Sweden) or at the Psoriasis association clinic (Sundbyberg, Sweden). 
The studies were approved by the Stockholm Regional Committee of Ethics and signed 
consent was collected from all the patients.  
 
3.2 BIOPSY COLLECTION AND CELL SUSPENSIONS (PAPER I, II, III AND IV) 
Six millimetre skin biopsies were collected from healthy skin, four millimetre biopsies were 
collected from patients with psoriasis. The biopsies were placed in 5 U/ml dispase (Life 
technologies) in PBS (Gibco) overnight at 4°C. After incubation, epidermis and dermis were 
separated and placed in a solution containing Collagenase III 570 U/ml (Worthington) DNase 
5 µg/ml (Roche) in Roswell Park Memorial Institute 1640 medium (RPMI 1640, Gibco) 
supplemented with 10% Fetal bovine serum (FBS, HyClone) and 100 U/ml Penicillin and 
Streptomycin (PEST, Gibco), for 90 minutes at 37°C. After incubation, the epidermal cell 
suspension was obtained by mechanical disruption of the tissue by repeated pipetting. The 
dermal cell suspension was obtained by repeated pipetting or after mechanical disruption with 
the Medicon/Medimachine system (BD Biosciences). The whole process is outlined in 
PAPER I, figure S1. 
 
3.3 PREPARATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS 
(PAPER II AND IV) 
Peripheral blood mononuclear cells (PBMCs) were prepared from 10-20 ml of peripheral 
blood using Ficoll Paque Plus (GE Healthcare) according to the manufacturer’s protocol. 
PBMCs were then cultured in RPMI 1640 supplemented with 10% FBS and 100 U/ml PEST 
until further use. In Paper IV, CD8+ T cells were negatively sorted from PBMCs using 
magnetic-activated cell-sorting MACS CD8 T cell isolation kit (Miltenyi Biotech) according 
to the manufacturer’s protocol. 
 
3.4 CULTURE AND STIMULATION OF DCS (PAPER I AND III) 
Epidermal and dermal cell suspensions were cultured in 1 ml RPMI 1640 supplemented with 
10% FBS and 100 U/ml PEST and left unstimulated or stimulated with 1 µg/ml 
lipopolysaccharide (LPS, Sigma Aldrich) or 1 µg/ml resiquimod (R848, GLSynthesis) for 6 
hours. Brefeldin A (GolgiPlug, BD Biosciences) was added to the culture to impede the 
release of intracellular cytokines into the culture media (PAPER I and III). For the induction 
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of IDO1 expression in PAPER III, the dermal cell suspension was cultured for 18 hours in 
presence or absence of IFN-g (10 ng/ml) and brefeldin A. After the incubation, cells were 
stained with antibodies directed against surface epitopes and, subsequently, against 
intracellular cytokines. 
 
3.5 CULTURE AND STIMULATION OF T CELLS (PAPER II AND IV) 
Epidermal and dermal cell suspensions and PBMCs were cultured in 1 ml RPMI 1640 
supplemented with 10% FBS and 100 U/ml PEST. Different combinations of TGF-b (2 
ng/ml), IL-2 (20 ng/ml), IL-15 (20 ng/ml), IL-1b (20 ng/ml), IL-23 (20 ng/ml) (all R&D 
Systems) and anti-CD3 (clone OKT3, Biolegend) were used as indicated in each figure to 
stimulate the cells for 1, 3 or 7 days. In some experiments (PAPER IV), epidermal and 
dermal cell suspensions and CD8+ MACS sorted PBMCs were stained prior culturing with 1 
µM carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) according to the 
manufacturer’s protocol. In brief, cells were resuspended in 1 ml PBS and stained with CFSE 
for 20 minutes at 37°C, then the residual dye was quenched by adding 5 ml RPMI 1640 
medium for 5 minutes at 37°C.  
For the assessment of the production of intracellular cytokines in PAPER II and IV, cell 
suspensions were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma 
Aldrich) and 1 µg/ml ionomycin (Sigma Aldrich) in presence of brefeldin A for 4.5 (PAPER 
II) or 5 (PAPER IV) hours. 
 
3.6 CULTURE AND STIMULATION OF HUMAN PRIMARY KERATINOCYTES 
(PAPER II) 
Six millimetre punch biopsies from healthy skin were placed in 5 U/ml Dispase in PBS and 
incubated overnight at 4°C. The following day, the epidermis was separated from the dermis 
and treated with 0.05% Trypsin/EDTA (Gibco) for 30 minutes at 37°C. A solution containing 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) and 10% FBS was used to interrupt the 
reaction. The obtained epidermal cell suspension was cultured in a cell culture flask pre-
coated with collagen I (Gibco) in EpiLife medium (Gibco) supplemented with human 
keratinocyte growth supplement (Gibco), 100 U/ml PEST and Fungizone (Gibco). The 
expanded keratinocytes were frozen for later use. 
Thawed keratinocytes were seeded in EpiLife medium supplemented with human 
keratinocyte growth supplement, 100 U/ml PEST and Fungizone in a 24 or 48 well plate at 
400000 cells/ml density. The following day, 35 nM Granzyme A (GzmA, Enzo Life 
Sciences), 10 ng/ml IL-17 or a combination of GzmA and IL-17 were added to the culture 
media and cells were incubated for 48 hours. In some experiments, 50 µM 3,4-
dichloroisocumarin (Enzo Life Sciences) was incubated for 1 hour at 37°C together with 
GzmA before adding it to the culture media. 
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3.7 LUMINEX-BASED MULTIPLEX IMMUNOASSAY AND ELISA ASSAY 
(PAPER II) 
The analytes released in cell culture supernatants were quantified using ProcartaPlex Human 
Cytokine & Chemokine Panel Immunoassay (eBioscience) and the plate was read by a Bio-
Rad Bio-Plex 200 System (Bio-Rad Laboratories). The amount of CXCL-1 released in cell 
culture supernatants was quantified using R&D Quantikine ELISA human CXCL1 (R&D 
Systems) and the plate was read by a Spectramax plus 384 reader (Molecular Devices). 
 
3.8 CONFOCAL MICROSCOPY (PAPER I, II AND III) 
Eight µm frozen skin sections were fixed by immerging them in 100% acetone for 5 minutes 
at 4°C (PAPER I and II) or by using the Foxp3/Transcription factor staining buffer set 
(Thermo Fisher) for 20 minutes at room temperature. After fixation, skin sections were 
incubated with Protein block (Dako) and incubated overnight with primary antibodies diluted 
in PBS containing 2.5% horse serum (Immunokemi) (PAPER II and II) and 
Foxp3/Transcription factor permeabilisation buffer (PAPER III). The following day, the skin 
sections were washed and stained with Alexa-based secondary antibodies of the appropriate 
species specificity (Life Technologies) and mounted with Vectashield mounting medium 
containing DAPI (Vector Laboratories). Images were acquired using Zeiss LSM780 (PAPER 
I and II) or LSM700 (PAPER III) confocal microscope (Zeiss) and processed using Fiji-
ImageJ. 
 
3.9 TRANSMISSION ELECTRON MICROSCOPY (PAPER I) 
Skin biopsies were fixed in 3% paraformaldehyde (Agar Scientific), moved to 2.5% 
glutaraldehyde (Ladd Research) and osmium tetroxide (TAAB Laboratories). Subsequently, 
skin sections were dehydrated and embedded in LX-112 (Ladd Research). Ultrathin sections 
were obtained by cutting the skin sections with a Leica EM UC 6 (Leica Microsystems) and 
contrasted using uranyl acetate and lead citrate. Images were acquired with a Tecnai 10 
transmission electron microscope (FEI) at 100 kV. 
 
3.10 FLUORESCENCE ACTIVATED CELL SORTING, RNA EXTRACTION AND 
RT-PCR 
Epidermal and dermal cell suspensions were stained with conjugated antibodies against cell 
surface epitopes and cells were sorted using MoFlo XDP (Beckman Coulter) (PAPER I and 
III) or BD FACSJazz (BD Biosciences) (PAPER IV). In PAPER I and III, sorted cells were 
collected in QIAzol lysis reagent (Qiagen) and mRNA was extracted using RNA Mini kit 
(Qiagen). The high-capacity RNA-to-cDNA kit (Applied Biosystems) was used to obtain 
cDNA from mRNA and TaqMan probes or TaqMan Low Density Array (Applied 
Biosystems) were used to analyse the gene expression by quantitative PCR. Gene expression 
was normalised against the house-keeping genes Ribosomal Protein Lateral Stalk Subunit P0 
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(DCs, PAPER I and III) or beta-2-microglobulin (T cells, PAPER III) and calculated as 
2(CT(Target Gene)-CT(House-keeping gene). 
In PAPER IV, sorted CD69-CD103-CD49a- dermal T cells were collected in RPMI 1640 
supplemented with 50% FBS and seeded in 96 well U bottom plate in presence of the 
cytokines previously enlisted. 
 
3.11 FLOW CYTOMETRY (PAPER I, II, III AND IV) 
Cells were collected and stained with Live/Dead Fixable Yellow Dead Cells kit (Thermo 
Fisher) in presence of human Fc receptor binding inhibitor (eBioscience, only when staining 
LCs and DCs). After washing, cells were stained with antibody cocktails directed against 
surface markers, then fixed and permeabilised using Cytofix/Cytoperm (BD Biosciences) and 
stained with antibodies directed against intracellular molecules. Samples were filtered 
through a 70 µm filter prior acquisition with CyAn ADP Analyzer (Beckman Coulter, 
PAPER I), LSRFortessa or LSRII (BD Biosciences, PAPER II, III and IV). Flow cytometric 
data and plots were analysed and generated using Flowjo version 9 (Tree Star). 
 
3.12 STATISTICAL ANALYSIS 
Mann-Whitney U test was used when comparing two groups with non-paired data, whereas 
the Wilcoxon matched-pair test was used when comparing two groups of paired data. The 
Kruskal-Wallis with Dunn’s multiple comparisons test was used when comparing more than 
one group. All the statistical calculations were performed using Graphpad Prism version 6 
and R (only PAPER I). All the plots were created with Graphpad prism except heat maps and 
spice charts in PAPER I, generated by MeV (TM4) and SPICE (NIH) respectively. P values 
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4 RESULTS AND DISCUSSION 
4.1 LANGERIN- DCS INFILTRATE THE SKIN IN LESIONAL PSORIASIS 
In healthy skin, LCs are the only antigen presenting cells that reside in epidermis. In active 
psoriasis, an additional population of HLA-DR+Langerin- cells infiltrates the epidermis, as 
shown by several reports (Alshenawy and Hasby, 2011, Fujita et al., 2011, Komine et al., 
2007, Lowes et al., 2005, Zaba et al., 2009). This is not an exclusive feature of psoriasis, 
since a prominent epidermal infiltration of DCs is also seen in atopic dermatitis (Baadsgaard 
et al., 1989). When these cells were visualised by confocal and electron microscopy, we 
confirmed that the infiltrated epidermal DCs (eDCs) did not express langerin nor contain 
Birbeck granules (PAPER I, figure 1). In figure 4.1 we show the fluorescence intensity 
profile graphs obtained by analysing images of healthy or psoriatic epidermis. The graphs 
depict the quantification of the fluorescence intensity of a given region, in this case along a 
250 µm line drawn across the fluorescent cells. The graphs clearly showed an overlap of the 
langerin and the CD74 (invariant chain of the MHC class II complex, thus identifying APCs) 
signals in healthy skin, whereas in psoriasis single-positive CD74 signals were detected. 







































































Figure 4.1. Infiltration of langerin- cells in lesional psoriatic epidermis. (A) Confocal microscopy 
image of healthy and lesional psoriatic skin. Langerin (red), CD74 (green), DAPI (blue). Scale bar: 50 
µm. (B) Plots depicting the fluorescence intensity of langerin (red) and CD74 (green) in healthy or 
psoriatic epidermis. 
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Next, the eDC population was phenotyped by flow cytometry in enzymatically-digested cell 
suspension. Two populations of CD11cbright and CD11cdimCD141+ were detected (PAPER I, 
figure 1 and S1). The composition of the DC subsets based on CD11c and CD141 were 
similar in eDCs and dDCs. CD11c and CD141 expression is not confined to resident DCs but 
is upregulated by a variety of other cell types in inflammation (Kashem et al., 2017, Loike et 
al., 1991, Maecker et al., 2012). Therefore, whether eDCs originated from translocated dDCs 
or blood derived DC precursors could not be assessed. However, the expression of CCR2, 
both at the mRNA and protein level, might indicate a monocytic origin (PAPER I, figure 2). 
By analysing the expression of CD1a and CD1c on eDCs and dDCs, we observed that a high 
proportion of dDCs did not express these markers, typically expressed on resident dDCs in 
healthy skin (PAPER I, figure 2), which might be an indication of the non-dermal origin of 
these cells. A previous study on TNF and iNOS producing dDCs in psoriatic lesions proposed 
that these cells infiltrated the skin from the circulation, based on their vicinity to blood 
vessels (Hansel et al., 2011). Our phenotypic profile could be a further indication that the 
increase in the number of dDCs in lesional psoriasis might be due to non-resident cells 
infiltrating the skin. LCs in psoriatic epidermis maintained similar levels of EpCAM 
compared to healthy LCs and, as expected, expressed high CD1a (PAPER I, figure 1-2). The 
enumeration of LCs in psoriasis is still an open debate. In our experimental setup, we 
identified and sorted LCs from healthy, non lesional psoriasis and lesional psoriasis by using 
EpCAM expression, and we did not find significant differences in the number of LCs/mm2 of 
skin (PAPER I, figure 2). Since we showed that the expression of EpCAM is comparable 
between healthy and lesional LCs and that sorted LCs expressed classical LC markers, such 
as LANGERIN, ECADHERIN and high CD1A (PAPER I, figure 2), we are confident that the 
sorted population is indeed composed by LCs.  
Gene expression analysis of sorted LCs from healthy skin and LCs and eDCs from lesional 
psoriasis showed differential gene expression in cells obtained from lesional psoriatic skin 
compared to healthy skin (PAPER I, figure 3). LCs upregulated IL15, important for T cell 
proliferation, and IL23A, involved in the generation of Th17/Tc17 T cells. Interestingly, 
comparable levels of IL15 mRNA were detected in LCs from non-lesional psoriasis 
compared to healthy LC, whereas IL23A mRNA was upregulated in both LCs from lesional 
psoriasis and non-lesional psoriasis (data not shown). This is an indication that, although LCs 
in non-lesional psoriasis display pro-inflammatory features, the gene expression of pro-
inflammatory cytokines is not generally upregulated in patients with psoriasis. Epidermal 
DCs expressed high levels of of pro-inflammatory cytokines, such as IL1B and IL6, and 
chemokines involved in macrophage, neutrophil (CXCL1), and lymphocyte (CCL22, CCL17) 
recruitment. In parallel, LCs and eDCs from lesional psoriasis upregulated numerous genes 
associated to tolerogenesis, such as PDL1, PDL2 (LCs and eDCs), IL10, ILT3 and IDO1 
(eDCs). This double pro-inflammatory/regulatory nature of cells in inflammation in human 
tissues is not surprising. In a previous work dissecting functional properties of T cells in 
psoriasis (Cheuk et al., 2014), sorted T cells from the epidermis of lesional psoriasis 
displayed high gene expression of both pro-inflammatory (IL17, IL22, IFNG, Granzymes and 
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perforin) and inhibitory genes (CTLA4, FOXP3 and IL10). Taken together, the gene 
expression profile of cells belonging to the DC compartment (PAPER I, figure 3) or to the T 
cell compartment (Cheuk et al., 2014) shows the complexity of the immune dysregulation in 
active psoriasis.  
 
4.2 LCS AND EPIDERMAL DCS FROM LESIONAL EPIDERMIS PRODUCE IL-
1b AND IL-23 
As shown by van der Aar and colleagues, LCs do not express TLR2, TLR4 and TLR5 (van 
der Aar et al., 2007), (table 1.7.1). Therefore, when we tested the capacity of LCs to produce 
cytokines in response to TLR stimulation, lipopolysaccharide (LPS)-stimulated LCs from 
healthy skin did not produce IL-1b, IL23 or IL-10 (PAPER I, figure 4), as expected. In 
addition, LCs from healthy skin did not respond to the stimulation with resiquimod (R848) 
(PAPER I, figure 4), ligand of both TLR7 and TLR8 present in the intracellular compartment 
of LCs (van der Aar et al., 2007) (table 1.7.1). Conversely, LCs from lesional psoriasis 
responded to both LPS and R848 stimulation with IL-23 production. In an independent study, 
IL-23 production by LCs from lesional epidermis was shown as a consequence of TLR2 
stimulation with zymosan (Sweeney et al., 2016). Collectively, the results shown in PAPER I 
and by Sweeney et al indicate a differential expression pattern (TLR2, TLR4) or activation 
threshold (TLR7/8) of TLRs on LCs from psoriatic skin. In accordance to the gene 
expression analysis (PAPER I, figure 3), eDCs displayed a high pro-inflammatory profile and 
produced both IL-23 and IL-1b after stimulation. It is important to highlight that eDCs 
produced IL-23 at similar or higher levels compared to dDCs, well known to produce IL-23 
(Cai et al., 2011, Lee et al., 2004, Teunissen et al., 2012, Tonel et al., 2010, Yawalkar et al., 
2009). In PAPER I, figure S1 we stained cryopreserved skin sections and analysed the 
localisation of CD74, langerin and CD3 expressing cells. As expected, CD74 and langerin co-
localised and exclusively identified LCs, whereas the single-stained CD74 cells identified 
eDCs. The images showed that LCs and eDCs in psoriatic epidermis resided in close 
proximity to epidermal T cells. Considered the DC-T cell vicinity and the capacity of LCs 
and eDCs to produce cytokines important for T cell proliferation and activation, it is possible 
that both LCs and eDCs contribute to trigger the resident T cells to maintain focal pathology. 
In the attempt to provide definitive proof that LCs stimulate T cells in psoriasis lesions, skin-
derived LCs, eDCs and dDCs were co-cultured with autologous blood-derived CD45RA- T 
cells in presence of the superantigen Staphylococcus Enterotoxin B. Proliferation and 
concentration of cytokines and chemokines released in the medium was assessed with flow 
cytometry and a multiplex immunoassay. The experimental design had several problems: 1) 
the number of cells recovered after sorting was very variable and did not allow reproducible 
co-culture conditions in terms of cell number and cell density in the wells; 2) LCs quickly 
died after sorting; 3) circulating T cells from patients with active psoriasis or during systemic 
treatment were more prone to secretion of cytokines compared to healthy T cells, thus the 
background levels were variable (figure 4.2.1);  and 4) the choice of using autologous T cells, 
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made to closely resemble the in vivo situation, led to poor T cell stimulation and, as a 
consequence, low concentration of analytes released in the supernatants. In conclusion, we 
did not manage to setup a sound system and the obtained results were not of such quality to 
be fit for publication.  
 
Despite the lack of this formal proof, the gene expression profile and cytokine production by 
LCs and eDCs, their vicinity to T cells and published data from independent studies 
(Sweeney et al., 2016) point towards an active pro-inflammatory role for LCs and eDCs in 





4.3 GRANZYME A PRODUCED BY T CELLS CONTRIBUTE TO CHEMOKINE 
RELEASE FROM KERATINOCYTES 
Psoriasis is a T cell-driven disease and T cells from lesional skin produce the cytokines IFN-
g, IL-17 and IL-22 (Cheuk et al., 2014, Hijnen et al., 2013, Lowes et al., 2008). Another 
essential function of CD8 T cells is cytotoxicity, mediated by granzymes (Gzms) and 
perforin, both upregulated at the RNA level in psoriasis (Cheuk et al., 2014, Suarez-Farinas et 
al., 2011). In addition to being upregulated during the active phase of psoriasis, GZMA is one 
of the genes that is retained at high levels, with less than 75% reduction after successful 

































Figure 4.2.2. Schematic of the events occurring in the skin in lesional psoriasis. Adapted from 
Eidsmo, Martini “Tillsammans skapar stationära och cirkulerande immunceller kaos i psoriasisplack”, 
BestPractice dermatologi, sep 2017. 
Figure 4.2.1. Peripheral blood T cells from healthy, lesional or 
treated individuals display differential IL-17 production after 
stimulation with SEB. Sorted CD8+CD45RA- T cells from 
peripheral blood were cultured for 5 days in presence of the 
staphylococcus enterotoxin B (SEB). The levels of IL-17A 
released in the culture media were assessed with a multiplex 
immunoassay.  
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In accordance to previously published gene expression data (Cheuk et al., 2014), CD8 T cells 
from lesional psoriasis displayed high levels of GzmA protein, but not of GzmB or perforin 
(PAPER II, figure 1 and figure 4.3).  
The presence of GzmA in CD8 T cells in the absence of perforin has previously been 
observed in lymph node tissue sections obtained from HIV infected patients (Andersson et 
al., 1999), but not in skin, nor in the context of psoriasis.  
To investigate if GzmA could affect skin homeostasis, we stimulated human primary 
keratinocytes with GzmA, alone or in combination with IL-17, and analysed the cytokines 
and chemokines released in the culture supernatant with a luminex-based multiplex panel. 
GzmA did not act alone, but in combination with IL-17, and caused an increase in the 
production of the chemokines CXCL1, CXCL12 and CCL4, known chemoattractants for 
neutrophils, lymphocytes and monocytes (PAPER II, figure 2 and S2). These results show an 
alternative function for GzmA outside its cytotoxic activity, which requires expression of 
perforin. Moreover, CD8 T cells may contribute to the pro-inflammatory environment in 
active psoriasis not only by producing cytokines, but also by enhancing keratinocyte-driven 





4.4 LCS FROM THE EPIDERMIS OF SUCCESSFULLY TREATED PATIENTS 
MAINTAIN A PRO-INFLAMMATORY PROFILE 
As previously mentioned, several strategies for the management of psoriasis are available, but 
these therapies do not cure psoriasis, and the disease comes back after therapy withdrawal. If 
the treatment is successful, the skin appearance ameliorates, and every sign of the previous 
inflammation disappears. Despite these fantastic macroscopic results, microscopic alterations 
persist in the skin (Suarez-Farinas et al., 2011). Epidermal T cells in resolved skin maintain a 
more active pro-inflammatory profile compared to dermal T cells, as displayed by their 
superior capacity to produce or co-produce IL-17 and IL-22 (Cheuk et al., 2014, figure 5). 
Taken the pro-inflammatory nature of resident T cells in resolved psoriasis, we next wanted 
to explore if neighbouring LCs and DCs accelerated or dampened this activity. We analysed 
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Figure 4.3. GzmA+ T cells reside in the skin in psoriasis. (A) Confocal microscopy image of lesional 
psoriatic skin. White line outlines the profile of the epidermis, arrows indicate T cells containing GzmA 
granules. GzmA (red), CD3 (green). (B) Plots depicting the fluorescence intensity of Granzyme A (red) 
and CD3 (green). 
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the DC compartment in the epidermis of patients with psoriasis after successful treatment 
with aTNF or UVB light therapies. By comparing the composition of the DC populations in 
non-resolved and resolved psoriasis plaques, we found that eDCs were restricted to the areas 
with ongoing disease (PAPER I, figure 5), therefore eDCs were absent from the epidermis 
after successful treatment with aTNF and UVB therapies. In contrast, LCs did not display 
variations in the number of cells/mm2 compared to healthy skin (PAPER I, figure 5). The 
gene expression data obtained from sorted LCs from healthy or resolved skin revealed a 
residual upregulation of IL23A and IL15 in LCs obtained from aTNF and UVB treated skin, 
respectively (PAPER I, figure 5), compared to healthy skin. We could not confirm the 
increased basal levels of IL-23 at a protein level, but when we stimulated LCs from aTNF 
treated skin with the TLR 7/8 agonist R848 we found increased IL-23 production, whereas 
LCs from healthy skin failed to do so, as previously shown (PAPER I, figure 5). Taken the 
vicinity of LCs and T cells in resolved skin (PAPER I, figure 5), into account, the results 
show that LCs can have the potential to stimulate resident T cells during both active and 
resolved disease (figure 4.2.2 and 4.4). In parallel, epidermal LCs in resolved psoriatic skin 
also retain their pro-inflammatory potential by quickly upregulating IL-23 after R848 
stimulation.  
 
4.5 T CELLS AND DCS FROM THE DERMIS OF SUCCESSFULLY TREATED 
PATIENTS DISPLAY TOLEROGENIC FEATURES 
Since dermal T cells are less active compared to their epidermal counterpart, we sought to 
investigate if T cells and DCs from resolved psoriatic skin presented a phenotype and 
functionality skewed towards tolerogenesis. Gene expression profiling of 45 genes in CD4 
and CD8 T cells sorted from aTNF and UVB treated skin highlighted expression of several 
markers associated to T cell inhibition or tolerogenesis. CTLA4 and the programmed cell 
death protein 1 (PD1) were upregulated in CD8 T cells sorted from UVB treated skin 
(PAPER III, figure 1). CTLA-4 is constitutively expressed on the surface of Treg cells and 
upregulated on activated T cells (Buchbinder and Desai, 2016, Takahashi et al., 2000). 
CTLA-4 is a T cell restricted marker that competes with CD28 on T cells for the binding to 
CD80 and CD86 present on the surface of APCs and binds these receptors with higher 
affinity (Collins et al., 2002). The binding of CTLA-4 does not result in an activation signal, 
as CD28 does, and affects T cell motility to impede T cell-APC engagement (Schneider et al., 









Figure 4.4. Schematic of the events occurring 
in the skin after successful treatment. Adapted 
from Eidsmo, Martini “Tillsammans skapar 
stationära och cirkulerande immunceller kaos i 
psoriasisplack” BestPractice dermatologi, sep 
2017. 
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its ligands result in inhibition of T cell proliferation, inhibition of the production of pro-
inflammatory cytokines and of cytokines important for T cell survival (Keir et al., 2008). PD-
1 has a broader expression compared to CTLA-4, and is present on B cells, NK cells, 
monocytes and DCs. PD-1 ligands, PD-L1, PD-L2 and CD80, are present on tissue cells and 
monocytes (PD-L1) or DCs (PD-L1, PD-L2 and CD80) (Keir et al., 2008). We did not find 
differences in the mRNA expression levels of CD80, CD86 (PAPER III, supplementary 
figure 2) or PDL2, while the expression of PDL1 was slightly upregulated in dDCs from 
aTNF treated dermis (figure 4.5.1). In the CD4 T cell compartment, we noticed the 
upregulation of FOXP3 regardless of the treatment strategy (PAPER III, figure 1). Foxp3+ T 
cells were visualised at the confocal microscope in UVB treated skin and were found in close 
contact with CD74+ APCs (PAPER III, figure 1).  
 
Thereafter, we sorted CD11c+ DCs from the dermis of aTNF and UVB treated patients and 
correlated their gene expression profile with healthy CD11c+ cells (PAPER III, figure 2). The 
gene expression of the AMP S100A8 remained upregulated after treatment, indicating 
residual low-grade inflammation, in accordance to previously published data (Gudjonsson et 
al., 2009, Suarez-Farinas et al., 2011). The interpretation of the upregulation of IL27 in DCs 
from treated dermis is more complicated, as IL-27 has both pro- and anti- inflammatory 
functions depending on the surrounding conditions (Yoshida and Hunter, 2015). On the other 
hand, ALOX15B was found to be upregulated in healthy skin compared to treated skin. This 
result confirmed previously published data on gene expression analysis of healthy, lesional 
and non-lesional skin, where ALOX15B was shown to be upregulated in healthy skin 
(Gudjonsson et al., 2009). Interestingly, no major differences were noticed when correlating 
the gene expression profile of DCs between the two treatment strategies, but some differences 
were evident when comparing dDCs from lesional psoriasis with dDCs from treated skin 
(figure 4.5.2). Overall, by comparing the gene expression correlation plots of epidermal LCs 
(PAPER I, figure 5) with the correlation plots of dDCs (PAPER III, figure 2 and figure 4.5.2) 



















































Figure 4.5.1. Expression levels of PDL1 and 
PDL2. Relative gene expression of PDL1 and 
PDL2 in sorted dermal CD11c+ cells from 
healthy, aTNF- or UVB- treated skin. 






One of the genes that was upregulated in dDCs obtained from both aTNF and UVB treated 
skin was IDO1. IDO1 is the first enzyme of the tryptophan metabolism pathway and is a 
limiting factor in the conversion of tryptophan to kynurenine. The depletion of tryptophan 
interferes with T cell proliferation and produces toxic metabolites, with the overall result of 
inhibiting T cell proliferation and activation (Mellor and Munn, 2004). IDO1 expression was 
highly upregulated in DCs from UVB treated skin, therefore we recruited a new cohort of 
UVB treated patients, generated the dermal cell suspension and analysed the protein 
expression of IDO1 by flow cytometry. In these patients, IDO1 displayed a trend towards 
increased expression in UVB patients and a high variation in healthy skin, but the difference 
between healthy controls and UVB patients was not statistically significant (PAPER III, 
figure 2). Further analysis of the phenotype of IDO1-expressing cells showed an enrichment 
in the CD1c+CD1a- subpopulation, indicating variations in the composition of the DC 
populations in UVB treated skin (PAPER III, figure 2). Interestingly, and in contrast to 
healthy skin, IDO1 expression was not upregulated in dDCs from UVB treated skin after 
IFN-g stimulation of the cell suspension, which might indicate saturated expression or 
incapacity of IFN-g alone to upregulate the production of IDO1 in dDCs from UVB treated 
skin (PAPER III, figure 2). In summary, the overall picture of the skin after psoriasis 
treatment shows that cells residing in the epidermis retain features of the disease (PAPER I, 
figure 5 and (Cheuk et al., 2014)), whereas both T cells and DCs in the dermis display anti-
inflammatory features (figure 4.4). This compartmental difference is important to keep in 
mind because it could lead to the design of therapeutic strategies aiming at taking advantage 
of the enrichment of anti-inflammatory cells in the dermis, with the aim of prolonging the 
time in remission after therapy withdrawal.  
 
4.6 ENVIRONMENTAL EFFECTS ON THE DEVELOPMENT AND 
FUNCTIONALITY OF TRM CELLS 
The composition of the Trm cell populations residing in the skin in the steady state differs 
between epidermis and dermis. The epidermis contains a high proportion of CD69+ Trm cells 
expressing CD103 or co-expressing CD103 and CD49a, whereas the majority of the Trm 



























































Figure 4.5.2. Differences in the gene expression profile between dDCs from lesional psoriasis or after 
treatment with aTNF or UVB. Gene expression correlation plots comparing sorted CD11c+ dDCs from 
lesional psoriasis, aTNF treated dermis or UVB treated dermis. Dotted line indicates 2-fold difference. 
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cells in the dermis only expresses CD69, with few cells co-expressing CD103 (Cheuk et al., 
2017, Cheuk et al., 2014, Watanabe, 2015, Wong et al., 2016). Previously published data 
revealed that T cells with shared clonality reside in both epidermis and dermis, therefore a 
common origin for epidermal and dermal Trm cells might be possible (Cheuk et al., 2017). 
Moreover, CD49a expression on CD103+ epidermal Trm cells is linked to the enhanced 
capacity to produce IFN-g, whereas the absence of CD49a favours the production of IL-17 
(Cheuk et al., 2017).  
In light of 1) the differential expression pattern of the Trm cell markers in the two skin 
compartments, 2) the differential environment established by the cytokines produced by LCs 
and DCs in epidermis and dermis and 3) differences in the skin milieu surrounding Trm cells 
in the steady state or in inflammation, we next set out to study the development and plasticity 
of skin Trm cells.  
To this end, we stimulated epidermal and dermal cell suspensions with a cytokine cocktail 
composed by TGF-b, IL-2 and IL-15 in presence or absence of anti-CD3 (aCD3). The 
components of the cytokine cocktail were chosen based on their relevance for T cell survival 
or formation of memory cells. IL-2 is important for the long-term survival of T cells in vitro 
(Hedfors and Brinchmann, 2003), although it has never been implicated in the formation of 
tissue resident T cells. TGF-b and IL-15 are instead important for the upregulation of CD103 
in mouse across different tissues (Casey et al., 2012, Mackay et al., 2013, Masopust et al., 
2006, Schenkel et al., 2016, Zhang and Bevan, 2013) and in human T cells from peripheral 
blood (Watanabe, 2015). Moreover, IL-15 can efficiently activate CD103+CD49a+ cells to 
exert their cytotoxic capacity (Cheuk et al., 2017). The requirement of antigen stimulation for 
the upregulation of resident markers is less clear. Since our experimental setup consists on the 
stimulation of a pool of T cells with unknown antigen specificity, a broad CD3 activation by 
an aCD3 antibody was used to mimic TCR engagement.  
In parallel to the skin cell suspensions, we stimulated magnetic-activated cell sorted (MACS) 
CD8+ T cells from peripheral blood mononuclear cells. As expected, the kinetics of the 
upregulation of resident markers in CD8 T cells from peripheral blood showed that the early 
activation marker CD69 was quickly upregulated already at day 1 and declined after 7 days 
of stimulation, whereas both CD103 and CD49a were slowly induced and reached high levels 
of expression at day 7 when cells were stimulated with TGF-b, IL-2 and IL-15 in presence of   
aCD3 (PAPER IV, figure 2). At day 1, blood-derived CD8 T cells did not express CD69, 
CD103 nor CD49a, whereas nearly all dermal and epidermal T cells expressed CD69 
(PAPER IV, figure 2, 3 and 4). After 7 days of stimulation, we observed an increase in the 
proportion of blood and dermal CD8 T cells co-expressing CD103 and CD49a. The 
combination of TGF-b, IL-2, IL-15 and aCD3 was most efficient in inducing CD103 in 
combination with CD49a (PAPER IV, figure 2 and 3). Interestingly, and contrary to the 
blood and dermal samples, epidermal T cells did not change the expression of the Trm cell 
markers when exposed to cytokines in combination with aCD3 (PAPER IV, figure 4). 
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The upregulation of CD103 and CD49a by IL-2 stimulation is interesting in itself. The IL-2 
receptor (IL-2R) is composed by the subunits alpha (IL-2RA, or CD25), beta (CD122) and 
gamma (CD132) (Minami et al., 1993). The beta and gamma subunits are also part of the IL-
15 receptor (IL-15R) (Budagian et al., 2006), but the alpha subunit is specific for the IL-2R. It 
has been shown that CD69+ cells collected from different human tissues (Kumar et al., 2017) 
including skin (Wong et al., 2016) express low levels of CD25, therefore it could be 
surprising that dermal cells responded to IL-2 stimulation, although the response of T cells to 
IL-2 signalling in absence of CD25 has been reported before (Hedfors and Brinchmann, 
2003). It is important to point out that the stimulation with TGF-b, IL-2, IL-15 and aCD3 did 
not only affect the expression of CD103 and CD49a, but also caused the downregulation of 
CD69. However, this downregulation was less pronounced in epidermal T cells compared to 
blood and dermal T cells: only 20% of the epidermal cells lost the expression of CD69 
(PAPER IV, figure 4), compared to 80% of downregulation in dermal cells (PAPER IV, 
figure 3). Taken together, these results indicate that dermal T cells have a high degree of 
phenotypic plasticity, whereas epidermal cells have a more rigid phenotype.  
We also analysed the proliferative capacity of epidermal, dermal and blood CD8 T cells by 
marking cells with carboxyfluorescein succinimidyl ester (CFSE) prior to stimulation. CFSE 
penetrates the cell-membrane, covalently binds to intracellular proteins and is equally divided 
between dividing cells, thereby the expression is decreased two-fold when the cells divide. 
By analysing the CFSE expression pattern, we observed that dermal CD103+CD49a- cells 
formed after stimulation with TGF-b, IL-2, IL-15 and aCD3 underwent multiple proliferation 
cycles, whereas the pattern of proliferation of the CD103+CD49a+ cells was donor-dependent 
(PAPER IV, figure 3). CD103+CD49a+ and CD103+CD49a- cells differentiated from blood-
derived CD8 T cells showed a comparable proliferation pattern (figure 4.6). The proliferative 
capacity of blood-derived cells was not consistent with that of dermal cells within the same 
donor (data not shown). Conversely, epidermal T cells belonging to both CD103+CD49a+ and 
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Figure 4.6. Proliferative capacity of CD103+CD49a+ and CD103+CD49a- cell populations differentiated 
from CD8+ peripheral blood cells. Cells were stained with 1µM CFSE and cultured for 7 days in presence of 
TGF-b, IL-2, IL-15 and aCD3. Representative histograms and graph depicting the proportion of cells undergone 
multiple proliferation cycles in the CD103+CD49a+ and CD103+CD49a- cell populations. 
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Next, the cytokine producing properties of in vitro derived CD103+CD49a+ and 
CD103+CD49a- cells were assessed with flow cytometry (PAPER IV, figure 5). We found 
that the magnitude of cytokine production was largely dependent on the type of stimulation 
received by the cells during the 7 days in culture. Few CD103+CD49a+ epidermal cells 
produced IFN-g after 7-day stimulation with TGF-b, IL-2, IL-15 and aCD3, whereas a high 
proportion of dermal CD103+CD49a+ cells produced IFN-g regardless of the stimulatory 
conditions. Conversely, IL-17 production was ascribed to the CD103+CD49a- population in 
the epidermis independently of the stimulation received by the cells, whereas it was confined 
to the CD49a- cells stimulated with IL-2 alone in the dermis (PAPER IV, figure 5).  
We have previously shown that LCs and eDCs contributed to the pro-inflammatory 
environment in lesional psoriasis by producing IL-1b and IL-23 (PAPER I) and we also 
showed that the type of stimulation received by epidermal and dermal cells for 7 days had a 
high impact on their cytokine production profile (PAPER IV, figure 5). To determine if pro-
inflammatory cytokines would affect the phenotype or functionality of the epidermal and 
dermal cells, we stimulated the cell suspensions with a cytokine cocktail containing IL-1b 
and IL-23 besides TGF-b, IL-2 and aCD3 for 7 days. The expression of CD103 and CD49a 
in dermal cultured cells increased and reached the same levels achieved after stimulation with 
TGF-b, IL-2, IL-15 and aCD3. Epidermal cells, as previously shown with other stimulating 
conditions, did not alter their expression of CD103 and CD49a. Strikingly, the epidermal 
cells responded with increased IL-17 production compared to the levels achieved after 
stimulation with TGF-b, IL-2, IL-15 and aCD3. This increase was noticed in both 
CD103+CD49a+ and CD103+ CD49a- cell populations, although CD103+CD49a- cells were 
still better at producing IL-17 compared to the counterpart. The results obtained in PAPER IV 
clearly highlight the influence of the environment on the expression of resident markers, and 
how T cells residing in different compartments of the skin (or in peripheral blood) respond in 
different ways to the inputs that might be present in their surroundings by changing the 
surface marker expression pattern or their functionality. Understanding these dynamics is 
important because it could lead to the possibility to influence the cell phenotype and function, 
and to the possibility to skew them towards a non-pathogenic profile. We have shown here 
that the magnitude of IFN-g and IL-17 production by the cells cultured for 7 days with 
different stimuli depends on the type of stimulation itself. Therefore, it is relevant to ponder 
over the consequences of cytokine-targeted strategies and how they might affect the 
composition and function of resident cells. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
Skin resident immune cells are instrumental for ensuring protection against foreign threats, 
but their role in maintaining localised inflammatory diseases is increasingly appreciated. In 
this thesis, individual immune cell subsets, in particular LCs, DCs and T cells, were 
characterised in different phases of psoriasis. Moreover, the development and function of 
resident T cells in healthy skin was investigated. Here, epidermal and dermal DCs and T cells 
were studied separately, instead of in full-thickness skin. 
In lesional psoriatic plaques, both resident and infiltrated immune cells contributed to the 
maintenance of a pro-inflammatory environment by secreting Th17/Tc17 skewing cytokines 
(PAPER I). The T cell derived granzyme A, in concert with IL-17, induced the release of 
neutrophil- and lymphocyte- attracting chemokines by keratinocytes, that might lead to the 
recruitment of additional pro-inflammatory cells perpetuating the inflammatory loop (PAPER 
II). The compartmentalised features of the skin immune system were evident when analysing 
DCs and T cells from resolved psoriatic skin after successful treatment. In the epidermis, LCs 
obtained from skin following anti-TNF inhibition therapy maintained the pro-inflammatory 
characteristics by producing IL-23 after TLR stimulation (PAPER I), whereas hints on the 
presence of anti-inflammatory DCs and T cells in the dermis from resolved psoriasis could be 
detected (PAPER III).  
Epidermal immune cells in resolved psoriasis, directly exposed to the external environment, 
responded more vigorously to stimulation compared to the cells situated in the deeper strata 
of the skin. One conclusion from my thesis work is that this pro-inflammatory immune cell 
reaction combined with the enhanced reactivity, or lower activation threshold, in 
keratinocytes in resolved lesions could cause a new disease flare. In parallel, inhibitory 
dermal cells seem to be anti-inflammatory.  
In healthy skin, different populations of Trm cells reside in epidermis and dermis. 
CD103+CD49a+ Trm cells are enriched in the epidermis, together with single positive CD103 
expressing Trm cells, whereas the dermis is almost completely devoid of these two 
populations. Here we showed that dermal Trm cells could acquire the expression of both 
CD103 and CD49a when stimulated with a cocktail comprising TGF-b, IL-2 and IL-15, 
important for their T cell stimulatory capacity and involved in the formation of Trm cells in 
mouse. Contrary to dermal Trm cells, epidermal Trm cells did not possess this phenotypic 
plasticity, but their IL-17 production levels were increased when stimulated with IL-23 and 
IL-1b (PAPER IV). These results further highlight the different nature of Trm cells residing 
in epidermis and dermis and show that epidermal cells still have the capacity to adapt to the 
input received from the outside. 
Future studies will aim at expanding the findings shown in PAPER IV, by analysing the 
phenotypic and functional characteristics of epidermal and dermal Trm cells from diseased 
skin. These studies would unravel potential differences in terms of phenotypic and functional 
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plasticity due to the different genetic background or differential capacity to respond to 
environmental clues. Moreover, it would be of great interest to sort CD103+CD49a+ and 
CD103+CD49a- cells from the epidermis or from the cultured blood or dermal T cells and 
compare their transcriptional and epigenetic profile. These analyses will reveal if the cells 
obtained after 7 days of culture are similar to bona fide Trm cells or if they retain clues of 
their origin.  
The experiments presented in this thesis show that it is possible to upregulate residency 
markers on dermal cells, but if these markers remain upregulated for a prolonged period of 
time or if they really confer residency to the cells is not known. One way to test this 
possibility is to transplant human skin on an immunodeficient mouse, deliver the cytokine 
cocktail to the skin and verify if the cells upregulate the residency markers in vivo, how long 
these markers remain upregulated and if the cells are retained into the skin. To verify if blood 
derived cells have the potential to generate a stable Trm cell population in the skin, it would 
be possible to sort peripheral memory T cells with skin tropism (CLA+), label these cells and 
transfer them to the mice, then deliver the cytokine cocktail to the skin and follow the fate of 
the labelled cells. If the establishment of these two systems is possible, the following step 
would involve the induction of skin infection to test if the “induced” Trm cells would confer 
better microbial protection or would establish an exaggerated immune response. 
A deep understanding of the phenotype, function and plasticity potential of resident DCs and 
T cells from different skin compartments would lead to targeted strategies aiming at 
eradicating or reprogramming resident immune cells, strategies that can be applied not only 
in the context of psoriasis but also in other inflammatory skin diseases or in skin 
malignancies. 
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